REVIEW ARTICLE
published: 31 July 2012
doi: 10.3389/fimmu.2012.00211
Immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome: a paradigm of immunodeficiency
with autoimmunity
Federica Barzaghi 1,2, Laura Passerini 1 and Rosa Bacchetta1*
1 Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy
2 Vita Salute San Raffaele University, Milan, Italy
Edited by:
Luigi Daniele Notarangelo, Harvard
Medical School, USA
Reviewed by:
Andrew Gennery, Newcastle
University, UK
Nancy Bunin, Children’s Hospital of
Philadelphia, USA
*Correspondence:
Rosa Bacchetta, San Raffaele
Telethon Institute for Gene Therapy,
San Raffaele Scientific Insitute, Via
Olgettina 58, 20132 Milano, Italy.
e-mail: rosa.bacchetta@hsr.it
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare
monogenic primary immunodeficiency (PID) due to mutations of FOXP3, a key transcrip￾tion factor for naturally occurring (n) regulatoryT (Treg) cells.The dysfunction ofTreg cells is
the main pathogenic event leading to the multi-organ autoimmunity that characterizes IPEX
syndrome, a paradigm of genetically determined PID with autoimmunity. IPEX has a severe
early onset and can become rapidly fatal within the first year of life regardless of the type
and site of the mutation. The initial presenting symptoms are severe enteritis and/or type￾1 diabetes mellitus, alone or in combination with eczema and elevated serum IgE. Other
autoimmune symptoms, such as hypothyroidism, cytopenia, hepatitis, nephropathy, arthri￾tis, and alopecia can develop in patients who survive the initial acute phase. The current
therapeutic options for IPEX patients are limited. Supportive and replacement therapies
combined with pharmacological immunosuppression are required to control symptoms at
onset. However, these procedures can allow only a reduction of the clinical manifesta￾tions without a permanent control of the disease. The only known effective cure for IPEX
syndrome is hematopoietic stem cell transplantation, but it is always limited by the avail￾ability of a suitable donor and the lack of specific guidelines for bone marrow transplant
in the context of this disease. This review aims to summarize the clinical histories and
genomic mutations of the IPEX patients described in the literature to date. We will focus
on the clinical and immunological features that allow differential diagnosis of IPEX syn￾drome and distinguish it from other PID with autoimmunity. The efficacy of the current
therapies will be reviewed, and possible innovative approaches, based on the latest high￾lights of the pathogenesis to treat this severe primary autoimmune disease of childhood,
will be discussed.
Keywords: IPEX, FOXP3,Treg, autoimmune enteropathy, neonatal diabetes, neonatal eczema, HSCT
INTRODUCTION
Immune dysregulation, polyendocrinopathy, enteropathy, X￾linked (IPEX) syndrome is a rare monogenic primary immun￾odeficiency (PID), characterized by multi-organ autoimmunity. It
is caused by mutations in the transcription factor forkhead box p3
(FOXP3), the master gene of T regulatory (Treg) cells. The dis￾ease shows an X-linked hereditary pattern: only males are affected,
whereas the carrier mothers are healthy.
Although IPEX syndrome is a rare disease, the recent increase
in the number of patients referred for diagnosis suggests that
the occurrence of the disease has been underestimated so far. At
present, 63 FOXP3 mutations have been published, for an overall
number of 136 patients described, and of these about half have
been diagnosed in the last 3 years. This also indicates that the
awareness of the disease has been growing with a better under￾standing of the role of FOXP3 and Treg cells in maintaining
peripheral tolerance.
Overall, the analysis of cases reported so far (Table 1) confirms
the relevance of the three main clinical manifestations and their
early onset while highlighting the occurrence of unusual symp￾toms. The genetic analysis is always requiredfor accurate diagnosis,
although other tests such as tissue biopsy and/or autoantibody
detection are important, as complementary tools, in the diagnostic
process and follow-up.
IPEX syndrome can be fatal in early infancy if not recognized,
therefore a timely diagnosis is essential to start appropriate treat￾ment. Treating IPEX patients poses a threefold challenge: autoim￾munity, infections supported by the autoimmune damage, and the
severity of the overall picture. Both novel and existing therapeutic
approaches will be discussed with an emphasis on the central role
of Treg cell impairment in the pathogenesis of IPEX syndrome.
GENETICS OF IPEX SYNDROME
Immune dysregulation, polyendocrinopathy, enteropathy, X￾linked syndrome was described for the first time in 1982 in a large
family with 19 affected males across five generations, as an X-linked
syndrome with diarrhea that was lethal in most male infants by
the first months or years of life (Powell et al., 1982). Only 20 years
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 1

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Clinical features, therapy and outcome in reported IPEX patients. Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

Peake et al.
(1996), Wildin
et al. (2001)
V6
f, 2
f c.1290_1309
del_insTGG
6 weeks Post
mortem
+
+
+
Peeling
skin
3170; 9999–
40,000µg/L
Anemia,
lymphadenopathy, sepsis
TPN, plasma IV Exitus
10 months
Ferguson et al.
(2000),
Bennett et al.
(2001b),
McGinness
et al. (2006)
F1-V1
f
,
V2
f, 1
f
c.1150G>A 1 month 9 years + − + 230–900;
755–3492
Pemphigoid nodularis;
bullous pemphigoid;
infections, asthma
PD, CSA,
dapsone, IgIV,
rituximab
Alive
14 years
Ferguson et al.
(2000),
Bennett et al.
(2001b)
F1-IV10
f c.1150G>A
# 2 months – −(Vomiting)
−
+ 936; 250 Hypothyroidism;
infection
na Exitus
10 months
F1-V4
f c.1150G>A
# 2 weeks – + + + 620; 30 Hypogammaglobulinemia,
infections, sepsis
IgIV Exitus
2 years
Ferguson et al.
(2000),
Bennett et al.
(2001b)
F1-V5
f
,
V7
f
c.1150G>A 3 weeks Post
mortem
−
+
+ 500; 22 Sepsis IgIV, CSA Exitus
12 weeks
Chatila et al.
(2000)
3-F1; F2
f
−14, 15,
27, 28
c.1044
+ 4A>G;
c.750_752
delGGA
3 weeks
−3 months
na 5/5 5/5 4/5 na; 4/5
hyper IgE
Autoimmune cytopenia
3/5, food allergy5/5
na Exitus
1/5, alive
4/5
Levy-Lahad
and Wildin
(2001), Wildin
et al. (2001)
1
f, F1
f c.1189C>T
# Birth – −(Atonic gut)
−
+ na Hypotonia,
hypothyroidism,
thrombocytopenia,
peritonitis, cholangitis
– Exitus
19 days
2
f, F1
f c.1189C>T Birth Post
mortem
−(Ileo) + − na Cachexia, hypotonia, thrombocytopenia,
peritonitis
– Exitus
5 weeks
3
f, F1
f c.1189C>T
# Birth – +
+
− na Infections, sepsis Dexamethasone,
CSA
Wildin et al.
(2001)
3na c.1113T>G na na + + + na Anemia HSCT Alive,
age na
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 2

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy 4na c.1150G>A na na + + + na Hypothyroidism, thrombocytopenia, sepsis na Exitus 4 months Bennett et al. (2001b), Kobayashi et al. (2011) F2, 5 c.1293_1294 delCT na na + − − na – HSCT Exitus age na Kobayashi et al. (2001, 2011), Fuchizawa et al. (2007), Otsubo et al. (2011) 1f, 1f, 3, 1f c.227delT 15 days na + − − na; + Thyroiditis, AHA, tubulonephropathy* FK506, betamethasone Alive 19 years Kobayashi et al. (2001, 2011) 2f, 4f c.1087A>G na na + + − na; + Thyroiditis, tubulonephropathy*, infections, sepsis na Exitus 3 years Baud et al. (2001) 1f c.1113T>G# na – + + Ichthyosis na ITP na Exitus 4.5 months 2f c.1113T>G 1 month 4 months + + Ichthyosis na; 1750 ITP, AHA, autoimmune neutropenia, cholestatic hepatitis MPD, FK506, HSCT Exitus 2 years 7 months Wildin et al. (2002), McMurchy et al. (2010) 1f c.1040G>A 3 months 13 years + + − na Infection (sepsis) PD, CSA, FK506, HSCT Exitus 14 years Wildin et al. (2002) 2 c.1044 + 459A > G <1 month na + + + na Lymphadenopathy, hepatosplenomegaly eczema, hypothyroidism, AHA, immune neutropenia, infections Steroids, rituximab, IgIV Alive 5 years 3f c.748_750 delAAG, c.543C>T 2 months 9 years + + − na Arthritis, ITP, hepatomegaly, mild hepatitis, progressive renal insufficiency Steroids, CSA, FK506, rofecoxib, MTX, rituximab, IgIV, HSCT Exitus 10 years(Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 3

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Continued Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

Owen et al.
(2003)
A-1
f c.227delT
# 2 weeks – + − + na Lymphoid infiltration of
the pancreas
na Exitus
6 weeks
A-2
f c.227delT 3 weeks na
+
−
+ na Hepatitis PDN, AZA, CSA Alive
10 years
Nieves et al.
(2004)
1na c.1150G>A 7 months 9 years + + + +; 33 Alopecia, longitudinal
ridging nails, autoimmune
neutropenia, severe
anemia, subclinical
thyroiditis
PD, CSA, IgIV,
G-CSF
Alive
11 years
Tanaka et al.
(2005),
Fuchizawa
et al. (2007),
Kobayashi
et al. (2011),
Otsubo et al.
(2011)
1, 4, 1, 3 c.1117T>G 2 months 4 months
+
−
− na;
2895–7275
– CSA, PD, IgIV,
HSCT
Alive
7 years
Bindl et al.
(2005)
1na c.968-
20A>C
7 years 10 years + − Dermatitis na; 17,370 CSA induced chronic
interstitial nephritis
Steroids, PD,
AZA, CSA, MTX,
rapa
Alive
15 years
2
f + <2 months
+
−
+ na; 3000 – Steroids, FK506,
AZA, rapa
Alive age
na
3
f + <2 months + − + na; 2000 – Steroids, FK506,
AZA, rapa
Alive age
na
Mazzolari et al.
(2005)
1na promoter
region
4 months <1 year
+
−
+ na; 763 sepsis MPD, CSA,
HSCT
Alive
2 years
4 months
Bacchetta
et al. (2006),
Gambineri
et al. (2008),
McMurchy
et al. (2010),
Passerini et al.
(2011b)
1, 12,
12, 12
c.1117-
1118TT>GC
neonatal 3 months + + + 768; 8423 – MMF, HSCT Alive
9 years
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 4

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy 2 f, 5f, 6f, 5f, 5f c.543C>T, c.970T>C neonatal + − + 2780; 374 Allergic asthma None Alive 7 years 3, 2, 1, 2 c.3G>A Neonatal <1 years + + + 552; 28,800 Hypothyroidism, lymphadenopathy, hepatosplenomegaly MPD, CSA, HSCT Alive 10 years De Benedetti et al. (2006) 1f c.454 + 4A>G 18 days 22 years + − + N; 200 Recurrent arthritis, psoriasiform dermatitis, hepatomegaly PD, MPD, CSA, FK506, infliximab Alive 22 years 2 c.323C>T 14 months 7 years + − − N; 74 Steroid-responsive pneumonia and pericarditis, recurrent arthritis PDN, PD, AZA alive 7 years Myers et al. (2006) 1na c.1-7G>T 1 day Post mortem + § − na Hypothyroidism, Infections na Exitus 54 days 2na c.1169G>A 4 days Post mortem + + + na Infections na Exitus <2 years Gavin et al. (2006) 1na c.210_210 + 1GG>AC na na + + + na; high AHA, ITP FK506, steroids, TPN Alive 5 months 2-p1f c.751_753 delGAG na na + + + na; high Thyroiditis, AHA Intermittent steroids Alive 6 years 2-p2f c.751_753 delGAG na na + + + na; high Thyroiditis FK506 Alive 9 years 3f g.-6247_- 4859del na na + - + na; high food allergies FK506 Alive 4 years Moudgil et al. (2007), Rao et al. (2007) 1, 2 c.303_304 delTT 4 months 6 months + + + –; 1564 Alopecia, AHA, lymphadenopathy, hypothyroidism, MGN, food allergies, infections TPN, CSA, PD, rituximab, HSCT Alive 4 years (Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 5

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Continued Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

Heltzer et al.
(2007)
1na c.817-1G>A birth Post
mortem
+ § Rush na; 5320 – FK506 Exitus
79 days
2na c.1061delC <2 months 2 years
+
−
+ na; 134 – NGT, infliximab,
illeostomy,
mercaptopurine,
steroids
Alive
4 years
3na c.210G>T 2 months na + − + na; 6 Recurrent airway
infections, ITP, motor
delay, hypoglycemic
seizures, anemia of
chronic diseases,
osteopenia,
hypogammaglobulinemia
TPN, NGT, Rapa,
IgIV
Alive
8 years
Rao et al.
(2007)
1na Splice
junction
Intron 9
na na
+
Colitis
na
+ na Food allergies, reactive
airways disease, AHA,
infections
Imuran, CSA, PD,
HSCT
Alive
9 years
3na c.1271G>A na na
+
Colitis
na
+ na food allergies, AHA, MGN,
infections
FK506, MMF, PD,
HSCT
Alive
5 years
4na c.1226A>G na na
+
Colitis
na
− na AHA TPN, FK506,
rituximab, PD,
alemtuzumab,
HSCT
Alive
1 years
Torgerson
et al. (2007),
Halabi-Tawil
et al. (2009),
Patey-Mariaud
de Serre et al.
(2009), Moes
et al. (2010)
IV.1
f, 6
f
,
8
f, 2na
g.-6247_-
4859del
3 weeks na + − + 950; >3000 Food allergies, cheilitis,
onychodystrophy,
recurrent infections,
sepsis, Hp gastritis
TPN, FK506,
Rapa
Alive
6 years
IV.2
f, 7
f
,
7
f, 1na
g.-6247_-
4859del
5 weeks na
+
−
+ 2400;
365–>2000
Food allergies, cheilitis,
recurrent infections,
sepsis
TPN, steroids,
FK506, AZA,
Rapa
Alive
9 years
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 6

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Lucas et al. (2007), McLucas et al. (2007) 1f Exon 10# <1 years 6 years + − Dermatitis na Hypogammaglobulinemia, anemia, pneumonias, laryngeal papillomatosis, Norwegian scabies TPN, HSCT Alive 7 years Burroughs et al. (2007) 1na c.1271G>A na na + + − na MGN HSCT Alive 6 years Fuchizawa et al. (2007), Otsubo et al. (2011) 2f, 2f c.1150G>A 2 months na − − + na Asthma, Adrenal Insufficiency Steroids Alive 10 years Fuchizawa et al. (2007) 3f c.1150G>A 19 days na + − + na – – Alive 15 years Suzuki et al. (2007) 1na c.1099T>C 8 days na + + + na Liver dysfunction, thrombocytopenia, sepsis na Exitus 4 months Taddio et al. (2007), Gambineri et al. (2008), Passerini et al. (2011b) 1, 11, 11 c.1150G>A Neonatal 6 years + + + 4900; 1494 Thyroiditis, alopecia, AHA, interstitial pneumonia Sterois, CSA, FK506, AZA, Rapa, IgIV Alive 16 years Lucas et al. (2008) 1f exon 10 3 months <1 years + − + 5400; na Thrombocytopenia, Aphthous stomatitis, EBV-induced lymphoma Rapa, Cx, VCR, PN Alive, 2 years 6 months Gambineri et al. (2008) 1 c.2T>C Neonatal Post mortem + + − 803; 3910 Sepsis MPD, CSA, FK506, IgIV Exitus 3 months Gambineri et al. (2008), Passerini et al. (2011b) 3, 3 c.210 + 2T>G Neonatal 6 months + + + 2187; na Hypothyroidism, hepatitis, sepsis MPD, CSA, FK506, AZA, IgIV, HSCT Alive 5 years Gambineri et al. (2008) 4na c.543C>T Neonatal 4 months + − − 710; 3 – MPD, CSA, IgIV Exitus 5 months 6na c.816 + 5G>A neonatal 1 years + + + na; 517 – PD, AZA Exitus 9 months Gambineri et al. (2008), Passerini et al. (2011b) 7na, 7na c.967 + 4A>G Neonatal <1 years + + + 700; >2000 Hepatitis MPD, FK506, AZA Alive 9 years (Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 7

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Continued Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

Gambineri
et al. (2008),
Passerini et al.
(2011b)
8na, 8na c.1015C>G Neonatal 5 months + + − na AIH, AHA,
hepatosplenomegaly
MPD, FK506,
AZA, Rapa
Exitus
6 months
Gambineri
et al. (2008),
McMurchy
et al. (2010),
Passerini et al.
(2011a,b)
9, 9, 9 c.1040G>T Neonatal 1 years
+
+
+ 498; 1966 AIH, AIT, anemia, food
allergy
PD, CSA Alive
15 years
Gambineri
et al. (2008),
McMurchy
et al. (2010)
10na
,
10na
c.1040G>T <1 year na Severe
chronic
gastritis
+ Xerosis na; >230 Pancreatic exocrine
failure, gastrectomy
MPD, CSA Alive
23 years
Gambineri
et al. (2008)
13na c.1121T>G Neonatal <1 year
+
−
+ na; 7000 Alopecia, AHA, AIT, CMV
infection
MPD, FK506,
AZA
Exitus,
11 months
Gambineri
et al. (2008),
Passerini et al.
(2011a,b)
14na c.725T>C 4 months 11 years + − + 1550; 5218 Sepsis, nephropathy MPD, PD, CSA,
FK506
Alive
15 years
Costa￾Carvalho et al.
(2008)
1
f c.1045-
3C>G
Birth na
+
+
+ N; na Hypothyroidism, AHA,
infections
na Exitus,
11 months
Yong et al.
(2008)
1 c.1061delC 2.5 years <5 years + − Dermatitis na Infections Steroids,
mesalazine,
infliximab, AZA,
6-MP, rapa
Alive
7 years
2
f c.210G>T 1 week 7 years
+
−
+ na Respiratory and GI
infections, AHA, ITP
IgIV, TPN,
steroids, rapa
Alive
8 years
Zhan et al.
(2008)
1na c.1139C>T 4 months 5 months + − − na; high – PDN, AZA,
FK506, TPN,
HSCT
Alive
3 years
Redding et al.
(2009)
1
f c.1150G>A 6 weeks na
+
−
+ 3753; 157 External otitis, sepsis,
bacteremia, AHA
CSA, PDN, HSCT Alive
2 years
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 8

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Halabi-Tawil et al. (2009) 1na c.1113T>G na na + e +Erythro- derm na Congenital ichthyosis, HA, recurrent infections, sepsis na na 2na c.736-1G>A na na + e +Erythro- derm na Cheilitis, HA, MGN, recurrent infections, sepsis na na 3na c.1101C>G na na + e + na Recurrent infections, sepsis na na 4na c.560C>T na na + e + Psori- asiform rash na Cheilitis, onychodystrophy, HA, recurrent infections na na 5na c.1121T>G na na + e + Psori- asiform rash na HA, MGN, recurrent infections, sepsis na na 8na c.751_753 delGAG na na + e − na HA, recurrent infections na na 9na c.751_753 delGAG na na + e − na HA, recurrent infections, sepsis na na D’Hennezel et al. (2009) 1 c.1150G>A birth <7 weeks + + Exfoliative der- matitis na Hypothyroidism, Respiratory Distress, Seizures, Renal Failure, Pancytopenia TPN, rapa Exitus 7 weeks Patey-Mariaud de Serre et al. (2009) 1na Truncated Protein 1.5 months na + − Dermatitis na; N AIT na na 2na truncated protein 6.5 years na + − Dermatitis na; N Allergic Asthma na na 3na c.1100T>G 1 year na + + − na; N tubulointerstitial nephritis na na 4na p.E251del 4 months na + + − na; high AHA, AIN na na 5na c.1121T>G 2 months na + + Dermatitis na; high AIT, AIN na na 6na c.1113T>G 4 months na + − Dermatitis na; N AHA, AIT na na 9na c.560C>T 11 months na + − Dermatitis na; high AIT, food allergy na na 10na p.E251del 7 months na + + − na; high AIT, AIN, tubulointerstitial nephritis na na 11na Truncated protein 6 months na + + Dermatitis na; N AHA, AIT, MGN na na 12na p.E251del 1 year na + − − na; N – na na (Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 9

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Continued Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

Hashimura
et al. (2009),
Otsubo et al.
(2011)
1
f, 4
f c.748_750
delAAG
2 months 5 years
−Vomiting + + na; 1141 Food allergy, nephrotic syndrome, infections,
AHA, sepsis
CSA, MPD Alive
5 years
Rubio-Cabezas
et al. (2009)
I c.1222G>A 2 days na
−
+
− na, N Nephrotic syndrome, TIA,
chronic diabetes
complications
na Alive
15 years
IIa
f c.1222G>A 3 weeks na + + − na; N Thyroiditis,
mucocutaneous
candidiasis, infections
na Alive
12 years
IIb
f c.1222G>A 3.5 months na
+
+
− na; N Thyroiditis,
mucocutaneous
candidiasis, infections
na Alive
12 years
III c.1010G>A 30 days na + + − na; 2266 – na Exitus,
13 months
IV c.1015C>G 1 week na Mal
digestion
+
+ na; N Thyroiditis na Exitus,
5.5 months
V c.227delT 1 day na + + − −;
132
Anemia, neutropenia,
thrombocytopenia,
dysthyroidism, infections
na Exitus
8 months
Scaillon et al.
(2009),
McMurchy
et al. (2010)
1na c.1040G>A 8 months 19 years Gastritis
+
− N; N Autoimmune gastritis,
pancreatic atrophy,
hypo-γ-globulinemia,
infections, bronchiectasis,
PDN Alive
22 years
Dorsey et al.
(2009)
1
f c.***878A>G neonatal 4.5 months
+ § + 850; >5000 Sepsis Rapa, MTX, PD,
HSCT
Alive
1 years
Burroughs
et al. (2010)
1na c.210
+ 2delT 2 months 2 months
+
+
− 1000–2000;
183
Hemolytic anemia,
infections
HSCT Alive,
4 years
9 months
2na c.816
+ 7G>C na 11 years + + − 2000; 842 Anemia,
steroid-dependent
interstitial lung disease,
membranous
nephropathy,
hypothyroidism, infections
HSCT Alive
17 years
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 10

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Harbuz et al. (2010) F1f – II3, II4, IV4, IV5, 3, 4, 5, 6 c.816 + 4A>G# na – 6/6 na na na sepsis PN Exitus <5 years 6/6 F2f – 1 c.816 + 4A>G 2 months Post mortem +Vomiting − + na; >4200 Sepsis Steroids, TPN Exitus 3 years Moes et al. (2010) 3na g.560C>T Birth na + − Skin pathol, High; 5500 Thrombocytopenia, Basedow hyperthyroidism, Hp gastritis, allergy FK506, HSCT Exitus 8 years 4na c.1121T>G Birth na + − + High; 8500 Hemolytic anemia, thrombocytopenia, allergy FK506, Rapa Exitus, 14 months 5na c.751_753 delGAG 6 weeks na + − + High; 12,500 Hypothyroidism, interstitial nephritis, hemolytic anemia, FK506, Rapa, HSCT Exitus 10 years 6na c.751_753 delGAG 4 weeks na + + Skin pathol na; 2150 AIH, hemolytic anemia, agranulocytosis FK506 Exitus 8 months 7na c.1015C>G 7 days na + + Skin pathol, noeczema na; 650 Hemolytic anemia FK506 Exitus 7 months Tsuda et al. (2010) 1 c.210 + 1G>A na na + + + na; 3700 Thyroiditis, hepatitis, nephropathy HSCT na 2 c.210 + 1G>A na na − − + na; 3210 nephropathy na na 3 c.543C>T na na + − − na; 1 – na na 4 c.816 + 7G>C na na + + + na; 842 Thyroiditis, nephropathy, recurrent infections na na 5 c.817G>T na na + − + na; 364 Thyroiditis na na 8 c.1150G>A na na + − + na; 2444 – na na 9 c.1157 G>A na na + − − na – na na 10 c.1169G>A na na + + + na; 2950 Recurrent infections na na 11 c.1190G>A na na + + + na; 657 – na na 12 c.***876A>G na na + − + na – na na Wang et al. (2010) 1na Intron1 2.5 months 2.5 months + + + na; + Thrombocytopenia, hepatitis, hypothyroidism, infections na Exitus 4.5 months An et al. (2011) 1f c.1080_1081 insA 20 days Post mortem + + + 9910; 75 Proteinuria, Sepsis Supportive treatment Exitus 1 month(Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 11

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 1 | Continued Reported by Pt
◦ Mutation Age at
onset
Age at
diagnosis
Diarrhea T1DM Eczema Eos
(/mm3);
IgE (IU/mL)
Additional
clinical
findings
Therapy Outcome

2
f c.1110G>A 14 days Post
mortem
+ − + 22; 681 Nephrotic syndrome,
lymphadenopathy,
splenomegaly, pneumonia
Supportive
treatment
Exitus
11 months
3
f c.970T>C 26 days Post
mortem
+
+
− 3450; 3 Pneumonia Supportive
treatment
Exitus
5 months
Bae et al.
(2011)
1 c.210
+ 1G>A 11 months 11 years + + − N; na PRCA, MGN, infections PD Alive
13 years
Kobayashi
et al. (2011)
2 c.1-23G>T na na
+
+
− na Nephrotic syndrome CSA, CS Alive,
age na
Otsubo et al.
(2011)
5
f c.210
+ 1G>T 6 months na + + − na; na Nephrotic syndrome CSA, steroids Alive
26 years
Kasow et al.
(2011)
1
f c.1150G>A 1.5 months <7 months
+
−
+
+; 157–1000 AHA, infections Rituximab, CSA,
PD, HSCT
Alive
3 years
7 months
Lopez et al.
(2011)
1 c.748_750
delAAG
2 months na + + + +; 45 AIH PD, CSA, AZA,
HSCT
Alive
6 years
Passerini et al.
(2011b)
17 c.1037T>C Neonatal <4 months
+
− Seborrhoeic
dermatitis
467; 1278 Infections, sepsis MPD, FK506,
HSCT
Alive
3 years
18 c.***876A>G Neonatal na + − Seborrhoeic
dermatitis
2300;
>2000
Hypotonia TPN, steroids,
CSA, HSCT
Alive
8 years
Passerini et al.
(2011a)
20 c.816
+ 2delT 5 months 27 years
+
−
+ 20; 424 AIT, osteomyelitis,
arthritis, S. aureus sepsis,
bronchitis
CSA, MPD, Rapa Alive
28 years
Pt, patient; Eos, eosinophils; na, not available; N, within normal ranges; e, unspecified endocrinopathy; ITP, idiopathic thrombocytopenic purpura; AIT, autoimmune thrombocytopenia; AIN, autoimmune neutropenia;
PRCA, pure red cells aplasia; MGN, membranous glomerulonephritis; AHA, autoimmune hemolytic anemia; HA, hematological abnormalities (cytopenias, hepatosplenomegaly, or lymphadenopathy); AIH, autoim￾mune hepatitis;TIA, transient ischemic attack; MSSA, Methicillin-sensitive Staphylococcus aureus; PN, parenteral nutrition;TPN, total parenteral nutrition; NGT, nasogastric tube; PD, prednisone; PDN, prednisolone;
CSA, cyclosporine; FK506, tacrolimus, MTX, methotrexate; AZA, azathioprine; Cx, cyclophosphamide; VCR, vincristine; HSCT, hematopoietic stem cells transplantation; FU follow-up; TNDM, transient neonatal
diabetes; GI, gastrointestinal.
*In this case, tubulonephropathy could be due both to the underlying disease or to tacrolimus.
◦Patient ID refers to the enumeration of patients as reported in the original publications listed in column 1.
§Hypo or hyperglycemia.
fPositive familial history.
#The mutation has not been studied in this patient but in other relatives with an IPEX phenotype belonging to the same gender.
The age written in the outcome column refers to the age of the patients at the latest follow-up from each publication.
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 12

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
later, in two unrelated kindred with IPEX phenotype, Chatila et al.
(2000) identified mutations in JM2 (later called FOXP3) in the
centromeric region of the X chromosome (Xq11.3-q13.3). Shortly
after, Bennett et al. (2001b) and Wildin et al. (2001) confirmed
that IPEX syndrome is the human equivalent of the scurfy mouse,
the natural mouse model of the disease, and identified mutations
in the FOXP3 gene in additional IPEX patients. Of note, in the
first family described in 1982, the disease mapped to the pericen￾tromeric region of the X chromosome (Bennett et al., 2000), but
no identifiable mutation on FOXP3 was found, so that it was sus￾pected to have a non-coding mutation that affects transcriptional
regulation or RNA splicing (Bennett et al., 2001b).
The highly conserved FOXP3 gene is composed of 12 exons
encoding a protein of 431 amino acids in humans. Among
the 63 mutations reported thus far (Figure 1), the majority of
them (27/63) alter the C-terminal forkhead (FKH) DNA-binding
domain of the protein, while the remaining of the mutations
occur outside the FKH domain. The latter include mutations
affecting the N-terminal proline-rich (PRR) domain (14/63), the
leucine-zipper (LZ) domain (5/63), the LZ-FKH loop (9/63), the
region upstream the initial ATG (3/63), and the C-terminal (3/63;
Figure 1).
Moreover, mutations of the polyadenylation site of the gene
(2/63) have been described, which lead to the expression of an
unstable FOXP3 mRNA and usually result in severe, early onset
disease (Bennett et al., 2001a; Dorsey et al., 2009; Tsuda et al.,
2010; Passerini et al., 2011b). Patients with mutations that abro￾gate expression of functional FOXP3 protein (i.e., missense or
frameshift mutations or splicing defects resulting in a premature
stop codon) tend to have severe presentation as well (Gavin et al.,
2006; Gambineri et al., 2008; Burroughs et al., 2010; An et al.,
2011). Nonetheless, the severity of the disease is not always depen￾dent on the absence of protein expression. The majority of affected
individuals have missense mutations (usually point mutations)
resulting in a normal or reduced level of expression of mutant
protein. Such mutations lead to an impaired transcriptional regu￾latory activity by altering the binding sites to DNA, the interaction
with other molecules (e.g., NFAT,AP1, RORα), or the dimerization
of FOXP3 (Figure 1).
Independently from the type or site of the FOXP3 mutation,
all patients described but five (Ferguson et al., 2000; Fuchizawa
et al., 2007; Rubio-Cabezas et al., 2009; Scaillon et al., 2009; Tsuda
et al., 2010; Otsubo et al., 2011) developed gastrointestinal symp￾toms (mainly diarrhea).The exact nature of genotype-phenotype
correlation has been difficult to pinpoint, especially considering
the age at onset and the disease outcome. For example, in 13
patients presenting with the same mutation (c.1150G>A), the
onset ranged from birth to 7 months (Table 1). In addition the
outcome was influenced by other factors such as timing of the ther￾apeutic intervention, concomitant infections, and each individual
patient’s response to therapy.
The histopathological lesions also differ among the patients
carrying the same mutation, further suggesting that the genotype
does not strictly correlate with phenotypical changes of the tar￾get organs (Patey-Mariaud de Serre et al., 2009). This inconsistent
correlation between genotype and phenotype may reflect the com￾plex intracellular interactions of FOXP3 (Allan et al., 2005) and
also strongly suggests the role of environmental or epigenetic fac￾tors that might participate in determining the clinical picture and
outcome (Gambineri et al., 2008).
CLINICAL MANIFESTATIONS
Most IPEX patients are born at term after an uneventful preg￾nancy from unrelated parents. A careful family history may reveal
the presence of male subjects in the maternal lineage with similar
clinical phenotype, early death, or multiple spontaneous abor￾tions. Notably, these patients may have other affected brothers,
but females belonging to the same lineage are usually healthy.
At birth, they may have a normal weight and length without
pathological findings. The onset of IPEX syndrome usually occurs
FIGURE 1 | Schematic representation of the FOXP3 gene reporting all the
mutations published so far. Annotations refer to both coding sequence and
protein, when applicable (www.ncbi.nlm.nih.gov/CCDS, accession number
CCDS14323.1). *c543C>T is a polymorphism. E, exon; Color code: orange,
N-terminal domain; green, zinc finger domain; blue, leucin-zipper domain; red,
forkhead domain.
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 13

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
in males within their first months of life, but in some cases even
after few days or weeks, and can be rapidly fatal if not diagnosed
and treated. The most severe cases are characterized by the early
onset of a triad of clinical manifestations: intractable diarrhea,
type-1 diabetes mellitus (T1DM), and eczema.
Autoimmune enteropathy is a hallmark of IPEX syndrome.
Patients present with neonatal, watery, and sometimes mucoid or
bloody acute diarrhea. This acute severe enteropathy often begins
in the first days of life or during breast-feeding, thus showing to
be independent from cow milk or gluten introduction in the diet.
However, it could be worsen by switching from breast-feeding to
regular formula. It typically persists despite dietary exclusions and
bowel rest. Since it results in severe malabsorption and significant
failure to thrive, parenteral nutrition is often required. In addition
to diarrhea, other gastrointestinal manifestations can present, such
as vomiting (Ferguson et al., 2000; Hashimura et al., 2009; Har￾buz et al., 2010; Otsubo et al., 2011), gastritis (Nieves et al., 2004;
Gambineri et al., 2008; Scaillon et al., 2009), ileus (Levy-Lahad and
Wildin, 2001), and colitis (Lucas et al., 2007; Otsubo et al., 2011;
Table 1).
Type-1 diabetes mellitus can precede or follow enteritis. T1DM
is present in the majority of patients including newborns, and
is usually difficult to control (Peake et al., 1996; Baud et al.,
2001; Gambineri et al., 2008). There have been rare cases (6/136)
presenting with diabetes mellitus without auto-antibodies (Rubio￾Cabezas et al., 2009; Scaillon et al., 2009). Imaging studies or
autopsy and histological examination often reveal destruction of
the pancreas and intense lymphocytic infiltrate, suggesting that
an immune mediated damage of this organ may have a role in
the pathogenesis (Wildin et al., 2002; Costa-Carvalho et al., 2008;
Rubio-Cabezas et al., 2009).
Cutaneous manifestations appear in the first months of life.
Similar to diarrhea and diabetes, cutaneous manifestations are
very common (95/136) and can be the first sign of the disease
(Table 1).
Dermatitis can be eczematiform (mainly atopic dermatitis)
(Wildin et al., 2002; Owen et al., 2003; Ruemmele et al., 2008),
ichthyosiform (Baud et al., 2001; Rao et al., 2007), psoriasiform
(Nieves et al., 2004; De Benedetti et al., 2006), or any combina￾tion of the above (e.g., atopic dermatitis and psoriasis coexisting
on different areas of the skin) (Halabi-Tawil et al., 2009). Skin
involvement is severe and diffuse, characterized by erythematous
exudative plaques that could evolve into more lichenfied plaques
(Halabi-Tawil et al., 2009). Pruritus can be a major complain
in these patients since it is intense and difficult to control with
anti-histamine drugs. Cutaneous lesions often show resistance to
classic treatments such as topical steroids or tacrolimus and can
be complicated by bacterial infections (most commonly Staphy￾lococcus aureus and epidermidis) with potential development of
sepsis (Halabi-Tawil et al., 2009). Other manifestations affecting
the integumentary system include: painful and fissurary cheilitis
(Halabi-Tawil et al., 2009), onychodystrophy (Halabi-Tawil et al.,
2009), and alopecia (Nieves et al., 2004; Moudgil et al., 2007;
Gambineri et al., 2008).
Two patients presented with severe allergies to food or other
allergens causing asthma, skin rashes, and gastrointestinal symp￾toms in the absence of endocrinopathies. These patients were
initially diagnosed and treated as severely allergic individuals
(Torgerson et al., 2007). Given this, severe allergic conditions in
association with other autoimmune symptoms should raise the
suspicion of IPEX syndrome.
The clinical picture can be complicated by the presence of other
autoimmune symptoms (Table 1): thyroiditis (27/136) with either
hyperthyroidism or, more commonly, hypothyroidism (Kobayashi
et al., 2001;Wildin et al., 2001, 2002; Nieves et al., 2004; Myers et al.,
2006; Moudgil et al., 2007; Costa-Carvalho et al., 2008; Gambineri
et al., 2008; Halabi-Tawil et al., 2009; Rubio-Cabezas et al., 2009;
Wang et al., 2010; Otsubo et al., 2011) cytopenias (42/136) such
as hemolytic anemia, thrombocytopenia, and neutropenia, and
hepatitis (8/136) that may be autoimmune with positive auto￾antibodies (Table 1). Renal disease can be related either to autoim￾munity or to prolonged administration of nephrotoxic drugs. They
are generally described as tubulonephropathy (Kobayashi et al.,
2001; Otsubo et al., 2011) and nephrotic syndrome (Gambineri
et al., 2008; Rubio-Cabezas et al., 2009; An et al., 2011; Otsubo
et al., 2011), although interstitial nephritis (Bindl et al., 2005;
Patey-Mariaud de Serre et al., 2009; Moes et al., 2010) and mem￾branous glomerulonephritis (Moudgil et al., 2007; Halabi-Tawil
et al., 2009; Burroughs et al., 2010; Bae et al., 2011) have also
been found in some patients’ histopathological examinations. A
rare manifestation associated with the milder forms of IPEX with
delayed diagnosis is arthritis involving one or more joints (Wildin
et al., 2002; De Benedetti et al., 2006). Splenomegaly and lym￾phadenopathy may progress as a result of an ongoing autoimmune
lymphoproliferation, as evidenced by the extensive lymphocytic
infiltrates in secondary lymphoid organs found in several patients
during autopsy (Wildin et al., 2002; Ochs and Torgerson, 2007;
Costa-Carvalho et al., 2008). Despite multiple and early autoim￾mune manifestations typical of IPEX syndrome, it is important to
underline that their number may increase with age. IPEX patients’
presentation typically begins early with some of these autoimmune
symptoms, and progresses with new manifestations over years.
The clinical spectrum can be worsened by infections, although
they are less frequent than the more prominent signs described
above. The onset of IPEX syndrome is often associated with infec￾tions, however a clear causative role of pathogens in the onset of
autoimmunity has not been demonstrated and infections can often
be the consequence of multiple immunosuppressive (IS) therapy
and poor clinical conditions.
The most frequent infections are pneumonia, airway infections,
gastrointestinal, and skin super-infections that may lead to life￾threatening sepsis from Enterococcus spp. and Staphylococcus spp.
(Halabi-Tawil et al., 2009). Other common pathogens are Clostrid￾ium difficile, Candida albicans, Pneumocystis jiroveci, CMV, and
EBV.
LABORATORY FINDINGS
Laboratory tests can be normal at onset. There are no specific diag￾nostic findings in IPEX syndrome although the laboratory abnor￾malities consistent with T1DM and severe enteropathy are com￾mon. Moreover, other alterations may suggest ongoing autoim￾mune manifestations in other target organs, such as hypothy￾roidism, cytopenias, hepatitis, or nephropathy. Markedly elevated
IgE levels and eosinophil counts are observed in the majority
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 14

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
of patients as an early hallmark of the disease (Table 1). Serum
IgA, IgG, and IgM levels are generally normal or low due to the
protein-losing enteropathy.
Patients in the acute phase of the disease, prior to IS therapy,
can have normal or elevated white blood cell counts. Leukocytosis,
if present, is due to an increase in lymphocytes but the percent￾age of the different lymphocyte subpopulations (CD3, CD4, CD8,
CD16, CD19) remains unchanged despite immune dysregulation.
The CD4/CD8 ratio is maintained or increased and the T cell
repertoire is polyclonal. The percentages of naive and memory T
cells are mostly comparable to their age-matched controls. The
CD4+CD25+FOXP3+ Treg cells are present (Gavin et al., 2006;
Gambineri et al., 2008), but FOXP3 expression can be reduced if
FOXP3 mutation prevents the expression of the protein (Bacchetta
et al., 2006) or if the patient is exposed to IS therapy (Gam￾bineri et al., 2008). In addition, in vitro proliferative responses
to mitogens are normal unless the patient is treated with IS drugs
(Bacchetta et al., 2006). The in vitro cytokine production shows a
decrease in Th1 cytokines and an increase in Th2 (Chatila et al.,
2000; Nieves et al., 2004; Bacchetta et al., 2006). The karyotype is
normal.
A variety of auto-antibodies are detected in most patients and
their presence usually correlates with signs of pathology in the tar￾get organs, but their production may also be a sign of immune
dysregulation without an obvious pathological linkage (Tsuda
et al., 2010).
There is increasing evidence that anti-enterocyte antibodies
are characteristic of IPEX patients, although not all patients
have been tested because the assay is not widely accessible. The
autoimmune enteropathy-related 75 kDa antigen (AIE-75), pre￾dominantly expressed in brush border of the small intestine and
proximal tubules of the kidney, has been identified as a specific tar￾get of the auto-antibodies present in IPEX patients sera (Kobayashi
et al., 1998, 1999, 2011; Gambineri et al., 2003; Patey-Mariaud de
Serre et al., 2009; Moes et al., 2010).
In addition, a recent study of Kobayashi et al. identified villin,
a 95-kDa actin-binding protein, as another brush border anti￾gen aberrantly targeted in IPEX syndrome. Like AIE-75, villin
is also expressed both in the microvilli of the small intestine
and in the proximal renal tubules. In this study, five out of five
IPEX patients showed anti-AIE-75 antibodies and four out of five
displayed anti-villin antibodies. None of the control sera from
healthy subjects or patients affected by non-IPEX pathologies (e.g.,
autoimmune enteropathies of different origin, enterocolitis, and
colon cancer) were positive for anti-AIE-75 antibodies and only a
few were weakly positive for anti-villin antibodies. High levels of
anti-villin auto-antibodies have been found only in children with
IPEX syndrome (Kobayashi et al., 2011). These findings confirm
the specificity of both anti-AIE-75 and anti-villin antibodies for
IPEX syndrome. Their link to the tissue damage, the correlation
to the progression of the disease, and their predictive value have
to be clarified.
Early presence of detectable auto-antibodies against insulin,
pancreatic islet cells, or anti-glutamate decarboxylase correlates
with occurrence of neonatal T1DM. Moreover, anti-thyroglobulin
and anti-microsome peroxidase antibodies are detected in
autoimmune thyroiditis even in the absence of functional
impairment; Coombs antibodies, anti-platelets antibodies, and
anti-neutrophils antibodies are often present in autoimmune
cytopenias; anti-smooth muscle (ASMA) and anti-liver-kidney￾muscle (anti-LKM) antibodies are positive in autoimmune hepati￾tis. Recently, Huter et al. (2010) reported that sera from IPEX
patients react against keratins, especially keratin 14, suggesting
this molecule as a target for autoreactive lymphocytes in the skin
of IPEX patients.
Although there is no pathognomonic finding specific to IPEX,
biopsies of the affected organs can help in excluding other etiolo￾gies. Main histological findings in the gastrointestinal tracts are
total or subtotal villous atrophy with mucosal lymphocytic and
eosinophil infiltration, but they are not specific for the disease. In
a recent work, Patey-Mariaud de Serre and colleagues described the
intestinal morphological changes of twelve IPEX patients (Patey￾Mariaud de Serre et al., 2009). Three different kinds of lesions
were found in the gastrointestinal tract: (1) the graft-versus-host
disease-like pattern was the most frequent form observed; (2) the
celiac disease-like pattern, found in two patients; (3) depletion of
the intestinal goblet cells along with the presence of anti-goblet
cell auto-antibodies, reported in one child. Hence, one of these
histopathological patterns in the proper clinical context and an
association with circulating anti-AIE-75 auto-antibodies would
suggest the diagnosis of IPEX syndrome.
In addition, one case reported the autoimmune destruction
of pancreatic exocrine cells contributing to the diarrheal disease
(Heltzer et al., 2007).
The histopathological changes at the skin biopsies are usually
non-specific for IPEX syndrome since there is a wide range of
possible dermatological pictures. The clinical and histopathologi￾cal features of skin pathology of 10 IPEX patients were described
by Halabi-Tawil et al. (2009). Either subacute /chronic spongiotic
dermatitis or psoriasiform changes, also consistent with a chronic
lichenified eczema, have been shown. One out of the four biopsies
showed a slight perivascular lymphocytic infiltrate in the upper
dermis, while the others showed a moderate to intense superfi￾cial dermal infiltrate with the simultaneous presence of eosinophil
and lymphocyte infiltrates. Although the majority of skin alter￾ations were compatible with atopic or psoriasiform dermatitis,
IPEX patients may present with uncommon allergic (Nieves et al.,
2004), autoimmune (Ferguson et al., 2000;McGinness et al., 2006),
or infectious (McLucas et al., 2007) dermatological complications.
DIFFERENTIAL DIAGNOSIS
A neonate presenting a single severe manifestation of IPEX syn￾drome such as enteropathy, diabetes, or newborn erythroderma
may pose a diagnostic challenge for the physician. For each of
them, the suspicion of IPEX syndrome should be raised once other
more common diseases have been excluded.
In a neonate presenting with isolated diarrhea, an autoimmune
pathogenesis of the enteropathy is a rare event. Table 2 provides
a summary of the possible causes of enteropathy in newborns
and infants. IPEX enteropathy, like other diarrheal diseases, may
have either an aggressive or insidious onset. When the onset of
the diarrhea is acute, microbial origins need to be excluded first.
When the diarrhea persists, a wide range of differential diagnosis
has to be considered (Murch, 2001). The most common cause is
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 15

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Table 2 | Differential diagnosis of early onset persistent diarrhea.
Infectious and post-enteritis diarrhea
FOOD-SENSITIVE ENTEROPATHY OR ENTEROCOLITIS
Cow’s milk sensitive enteropathy (most frequent)
Celiac disease
Non-celiac gluten sensitivity
Food protein induced enterocolitis
Eosinophilic gastroenteropathy
ANATOMICAL DEFECTS AND DYSMOTILITY DISORDERS
Hirschsprung disease
Intestinal lymphangiectasia
Short bowel syndrome (post surgery)
Stagnant loop syndrome (post surgery)
Chronic intestinal pseudo-obstruction
TRANSPORT DEFECTS
Chloride-bicarbonate exchanger defect (chloride-losing diarrhea)
Sodium hydrogen exchanger (congenital sodium diarrhea)
Ileal bile acid receptor defect
Sodium-glucose cotransporter defect (glucose-galactose malabsorption)
Abetalipoproteinemia
Hypolipoproteinemia
Acrodermatitis enteropathica (zinc deficiency)
ENZYMATIC DEFECTS
Enterokinase deficiency
Disaccharidase congenital defect (lactase, sucrase-isomaltase)
PANCREATIC MALABSORPTION
Cystic fibrosis
Shwachman syndrome
PRIMARY EPITHELIAL CAUSES OF INTRACTABLE DIARRHEA
Microvillous inclusion disease
Tufting enteropathy
Heparan sulfate deficiency
IMMUNODEFICIENCIES (USUALLY UNMASKED BY A PATHOGEN)
Severe combined immunodeficiency (SCID)
Thymic hypoplasia
Class II major histocompatibility (MHCII) deficiency
CD40 ligand deficiency
Neutrophilic specific granule defect
Acquired immunodeficiency syndrome (AIDS)
IBD (very rare in infancy, to be considered as a part of a PID)
METABOLIC DISEASES
Mitochondrial myopathy
Wolman disease
AUTOIMMUNE ENTEROPATHY
food-sensitive enteropathy, so appropriate exclusion diets should
be initiated for an adequate period. Anatomical abnormalities
such as malrotation and pseudo-obstruction may cause bacterial
overgrowth with chronic diarrhea and malabsorption. If chronic
diarrhea is associated to protein-losing enteropathy, lymphangec￾tasia should also be considered. Transport or enzyme disorders
induce selective malabsorption of glucose-galactose, lipids, fat￾soluble vitamins, amino acids, electrolytes, and zinc (Murch, 2001,
2006). In some of these cases, diarrhea would be abrogated by with￾drawing oral feeding. Moreover, malabsorption could be in some
cases related to pancreatic disease rather than to an intestinal trans￾port or enzymatic alteration. Nevertheless, the intestinal biopsies
in both cases show a normal architecture with intact villous￾crypt axis, unlike in IPEX. On the contrary, primary epithelial
enteropathies, such as microvillous inclusion disease and tufting
enteropathy, are characterized by blunting villi at the intestinal
biopsy and usually appear in the first days after birth. They should
be excluded if diarrhea is prolonged and continues during total
parenteral nutrition (Sherman et al., 2004). Immunodeficiencies,
such as severe combined immunodeficiency (SCID) or interme￾diate forms of combined immunodeficiency (CID), may present
first with gastrointestinal symptoms, often fatal in early childhood
if untreated (Geha et al., 2007). In the latter cases, diarrhea may
be due to a prolonged impairment to clear enteric pathogens or
to a primary concomitant autoimmunity. Even metabolic diseases
or endocrinopathies could manifest with chronic diarrhea. Fur￾ther metabolic and hormonal assessment should be considered
in such cases. Autoimmune enteropathy is usually a diagnosis of
exclusion. Once the aforementioned diseases have been excluded
by appropriate clinical or laboratory evaluations, the presence of
the following clinical and histological findings indicative of the
autoimmune pathogenesis, should be considered: an unrespon￾siveness to dietary restriction and total parenteral nutrition, an
association with other autoimmune conditions (Unsworth and
Walker-Smith, 1985), small intestinal villous atrophy with hyper￾plastic crypt, mononuclear cells infiltrate within the intestinal
mucosa (Murch, 1997). Autoimmune enteropathy can be also one
of the symptoms of complex forms of immune dysregulation, but
other clinical or laboratory features usually help to distinguish
them from IPEX syndrome (Table 4).
The onset of permanent diabetes mellitus in the neonatal age
is described as a rare event (Rubio-Cabezas et al., 2010). Although
autoimmune T1DM is diagnosed in over 95% of children present￾ing with diabetes after 6 months of age (Porter and Barrett, 2004),
alternative etiologies should be considered in newborns and young
infants presenting with diabetes before 6 months of age (Hatter￾sley et al., 2009). Most of these patients have a monogenic form
of disease, even if the responsible gene remains unknown in up to
40% of patients (Edghill et al., 2008). The main monogenic causes
of early onset diabetes are mutations in Kir6.2 gene (the inward
rectifier subunit of the ATP-sensitive potassium channel of the β
cells), in SUR1 gene (the regulatory subunit of the KATP channel
in pancreatic β cells) and in the preproinsulin gene. Mutations of
chromosome 6q24 and mutations of the insulin gene may also be
considered (Valamparampil et al., 2009; Greeley et al., 2010). The
presence of auto-antibodies specific for pancreatic antigens before
6 months of age should however pose the question of FOXP3
mutation (Greeley et al., 2010). A recent study reported that 4%
of male patients with permanent neonatal diabetes were found to
have FOXP3 mutations (Rubio-Cabezas et al., 2009). The diag￾nosis of IPEX becomes more obvious when diabetes is preceded
or followed by other symptoms related to immune dysregulation,
such as enteropathy and eczema.
Skin pathology is a common finding in infants diagnosed with
IPEX syndrome. The absence of other clinical signs may delay
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 16

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Table 3 | Differential diagnosis of erythroderma presenting in the
neonatal period.
INFECTIONS
Staphylococcal scalded skin syndrome (SSSS)
Congenital cutaneous candidiasis
IMMUNODEFICIENCY
Graft-versus-host disease (GvHD) with underlying SCID
Omenn’s syndrome
ICHTHYOSES
Non-syndromic ichthyoses (non-bollous ichthyoses, bollous ichthyoses)
Syndromic ichthyoses (Netherton’s syndrome, Conradi–Hünermann
syndrome)
METABOLIC DISEASES
Multiple carboxylase deficiencies
Essential fatty acid deficiency
DRUGS
Ceftriaxone
Vancomycin
OTHER SKIN PATHOLOGIES
Infantile seborrheic dermatitis
Atopic dermatitis
Psoriasis
Cutaneous mastocytosis
the diagnosis, especially in neonates and infants (Nieves et al.,
2004). The presentation ranges from mild eczema to severe gen￾eralized erythroderma or other unusual skin manifestations with
poor response to steroids (Halabi-Tawil et al., 2009; Redding et al.,
2009). Focusing on the neonates and infants presenting erythro￾derma as single diffuse manifestation of IPEX syndrome at onset,
Table 3 summarizes the possible clinical pictures that should be
considered for differential diagnosis (Hoeger and Harper, 1998;
Fraitag and Bodemer, 2010). Erythroderma is an inflammatory
skin disorder affecting the majority of the body surface, with sub￾acute or chronic evolution accompanied by scaling skin. In the
neonatal period, it can also be the primary manifestation of several
conditions. Perinatal or neonatal infections such as Staphylococcal
scalded skin syndrome (SSSS) and congenital cutaneous candidi￾asis may result in diffuse skin involvement. Skin swab and/or skin
biopsy is usually diagnostic.
Immunodeficiencies may present with extended skin alter￾ations as a result of the immune aggression sustained by autoreac￾tive newborn’s lymphocytes (as in Omenn’s syndrome) or mater￾nal lymphocytes expanding after birth in the immunodeficient
host (graft-versus-host disease with underlying SCID). Immuno￾logical assessment confirms the diagnosis of PID in these cases
(Table 4). If ichthyoses is suspected, skin biopsy is diagnostic.
Metabolic disorders can be associated with erythroderma, but usu￾ally it is not the only complain and other systemic signs can support
the diagnosis. Ceftriaxone or Vancomycin, if recently adminis￾tered, should be stopped immediately to rule out drug-induced
skin reactions. Other common skin pathology of infancy, e.g.,
atopic eczema and psoriasis, may evolve into erythroderma, but
the early presentation, the persistency of the lesions, and the lim￾ited response to topical treatment may increase the suspicion of
IPEX syndrome. As recently pointed out by Leclerc-Mercier et al.
(2010), early skin biopsy has a central role in excluding the majority
of these pathological conditions.
The clinical characteristics that are common in PID with
autoimmunity and unique to IPEX are summarized in Table 4.
The differential diagnoses with primary immunodeficiencies asso￾ciated with immune dysregulation and subsequent autoimmune
phenomena, such as CD25 deficiency, STAT5b deficiency,Omenn’s
syndrome, Wiskott–Aldrich syndrome, Hyper IgE syndrome,
autoimmune lymphoproliferative syndrome, autoimmune poly￾endocrinopathy candidiasis ectodermal dystrophy, should always
be considered.
FOXP3 DYSFUNCTION AND DISEASE PATHOGENESIS
Forkhead box p3 is a transcription factor, master regulator for
the function of thymic-derived regulatory T (nTreg) cells (Wildin
et al., 2001; Fontenot et al., 2003; Bacchetta et al., 2007; Gambineri
et al., 2008). These cells are among the main subsets of CD4+ T
cells appointed to maintain peripheral self-tolerance.
CD4+CD25+FOXP3+ T cells can be present in normal per￾centage in the peripheral blood of the IPEX patients. This was
demonstrated not only by immunophenotype, but also by analy￾sis of the Treg-cell-specific-demethylated-region (TSDR; Passerini
et al., 2011b; Barzaghi et al., 2012), whose demethylation ensures
cell-specific stable expression of FOXP3 (Baron et al., 2007; Wiec￾zorek et al., 2009).Therefore, in IPEX patients FOXP3mut Treg
cells are physically present but functionally impaired, and this is
considered the primary direct cause of autoimmunity in IPEX
(Bacchetta et al., 2006; D’Hennezel et al., 2009; Moes et al., 2010).
In this respect, IPEX syndrome is the best example of monogenic
autoimmune disease due to Treg deficiency. However, autoimmu￾nity in other immunodeficiencies, such as ADA-SCID and WAS,
has been recently associated with altered function of Treg cells,
regardless of FOXP3 expression (Marangoni et al., 2007; Sauer
et al., 2012).
Despite the general consensus on the fact that FOXP3 is funda￾mental for acquisition and maintenance of suppressive function
by nTreg cells (Gavin et al., 2007; Wan and Flavell, 2007; Williams
and Rudensky, 2007), it is unclear how the different mutations
affect their function. Functional in vitro studies on Treg cells of
IPEX patients revealed that the degree of functional impairment of
the suppressive activity varies among the patients, with complete
abrogation of suppressive function in patients with null mutations
(Bacchetta et al., 2006). Similarly, mutations in the FKH DNA￾binding domain of FOXP3 that caused severe IPEX (p.R347H and
p.F373A) were only partially blocked in their ability to reprogram
conventional T cells into Treg cells (McMurchy et al., 2010). It may
therefore be hypothesized that some mutated forms of the pro￾tein retain residual protein activities, thus only partially impairing
FOXP3 functions. The molecular mechanisms of Treg-mediated
suppression remain controversial, hence our understanding of the
impact of different FOXP3 mutations on Treg cell function is
incomplete.
In addition to the well-accepted loss of suppressive function,
we recently described that FOXP3 mutations cause high insta￾bility of the Treg cell compartment, with a marked shift to the
Th17 cell phenotype of bona fide nTreg cells expressing a mutated
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 17

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 4 | Differential diagnosis of primary immunodeficiencies (PID) presenting with autoimmunity. IPEX CD25 def STAT5b def OMENN’S WAS HIES ALPS APECED Onset Neonatal, 1 year <1 year, early infancy <1 year, infancy Neonatal, 1 year 1 year, early infancy Neonatal, 1 year Neonatal, 1 year Infancy, young adulthood Enteropathy Always Frequent Frequent Frequent Possible Not present Not frequent Not frequent Endocrinopathy T1DM
± thyroiditis Thyroiditis GH unrespon￾siveness Absent Absent Absent Absent Hypoparathyroidism, adrenal insuffi￾ciency
±T1DM,
thyroiditis
Skin lesions Eczema,
erythroderma
Eczema,
erythroderma
Eczema Erythroderma,
alopecia
Eczema Newborn rash,
eczema
Urticarial rash Alopecia, vitiligo
Infections Rare/secondary to IS Recurrent/
persistent
(particularly CMV)
Recurrent
(viral), severe
varicella
Severe Frequent Recurrent
pulmonary,
cutaneous
(S. aureus)
Not frequent Candidiasis
Anemia Possible Possible Rare Frequent Possible Absent Frequent Rare
Thrombocytopenia Possible Possible Rare Possible Always Absent Frequent Rare
Neutropenia Possible Possible Rare Rare Rare Rare Frequent Rare
Others Failure to thrive,
hepatosplenomegaly,
lymphoadenopathy,
other autoimmune
manifestations
Failure to thrive,
hepatosplenomegaly,
lymphoadenopathy
Growth failure,
chronic lung
disease,
interstitial
pneumonia
Failure to thrive,
hepatosplenomegaly,
lymphoadenopathy,
inflammatory
pneumonitis and
enteritis
Failure to
thrive,
hemorragies,
other
autoimmune
manifestations,
tumors
Characteristic
face, cathedral
palate, bone
fractures
Hepatosplenomegaly,
lymphadenopathy,
other autoimmune
manifestations
Ovarian or testicular
failure, gastritis,
hepatitis,
keratoconjunctivitis
Eosinophilia/hyper
IgE
Present Present Present Present Present Present Absent Absent
Hereditary pattern X-linked AR AR AR/unknown X-linked AD/AR/
unknown
AD/unknown AR
Gene FOXP3 IL-2RA (CD25) STAT5b RAG1/2 (90%),
Artemis/IL7RA/,
ADA/DNAligase
IV/γc/unknown
WASP STAT3/TYK2/
DOCK8/
unknown
FAS/FASL/CASP8/
CASP10/unknown
AIRE
WAS, Wiskott–Aldrich syndrome; HIES, hyper IgE syndrome; ALPS, autoimmune lymphoproliferative syndrome; APECED, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; def, deficiency; IS,
immunosuppression; T1DM, type-1 diabetes mellitus; AR, autosomal recessive; AD, autosomal dominant.
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 18

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
form of FOXP3 (Passerini et al., 2011b). Indeed, the plasticity
between different CD4+ T cell subsets is a new and dynamic con￾cept, particularly pronounced between the Th17 and Treg cell
compartments (Lee et al., 2009), although the in vivo relevance
of such phenomenon is controversial (Zhou et al., 2009; Rubtsov
et al., 2010). Thus, in addition to the loss of suppressive function,
FOXP3 mutations are associated with inflammation-driven con￾version from a regulatory to an effector (i.e., IL-17-producing)
phenotype of mutated Treg cells, which may directly contribute to
the autoimmune damage in the target organs.
While the necessity of FOXP3 for suppressive function of Treg
cells is undisputed, it is unclear whether functional FOXP3 is
essential for thymic development of Treg cells in humans. Data
from murine models of FOXP3 deficiency indicate that FOXP3
is dispensable for thymic development of Treg cells, but rather
essential for their maintenance in the periphery, as demonstrated
in Foxp3gfpko female mice (Gavin et al., 2007) and in FILIG mice,
which display reduced Foxp3 expression in Treg cells (Wan and
Flavell, 2007). On the other hand, data from healthy carriers
of FOXP3 mutations and transplanted IPEX patients with low
peripheral donor chimerism clearly indicate that only Treg cells
expressing a wild type FOXP3 survive long term in the periphery,
although leave it unclear whether the selective advantage is already
active during thymic differentiation or occurs later on in life (Di
Nunzio et al., 2009; Seidel et al., 2009). Our recent observation that
bona fide Treg cells can be detected by TSDR demethylation analy￾sis in the peripheral blood of IPEX patients both at the onset of the
disease and several years after IS treatment, regardless of FOXP3
expression, demonstrates that functional FOXP3 is not necessary
for thymic differentiation of Treg cells in humans, as previously
demonstrated for murine Treg cells (Gavin et al., 2007), and that
FOXP3mut Treg cells can survive and be detected long term, in the
peripheral blood of patients with IPEX syndrome (Passerini et al.,
2011b; Barzaghi et al., 2012).
Evidences from studies on human and murine models show
that Type-1 regulatory T (Tr1) cells can contribute to suppress￾ing the development of autoimmunity in addition to nTreg cells
(Roncarolo et al., 2006; Sakaguchi, 2006). We recently demon￾strated that Tr1 cells can develop in IPEX patients regardless of
FOXP3 expression (Passerini et al., 2011a). This observation sug￾gests that FOXP3-independent immune regulation can potentially
contribute to controlling the disease, although Tr1 cells alone do
not seem adequate to suppress the initial acute phase of the dis￾ease. Thus, it is tempting to conclude that FOXP3 is not necessary
for function and development of adaptive Treg cells, the IL-10
producing Tr1 cells.
In humans, FOXP3 is also expressed transiently upon activa￾tion, in conventional Teff cells (Allan et al., 2007; Tran et al., 2007;
Passerini et al., 2008), in which a still unknown function has been
postulated (Ziegler, 2006; McMurchy et al., 2010). This implies
that FOXP3 mutations may also impinge on Teff cell function
and suggests that FOXP3-dependent Teff impaired function may
directly contribute to the pathogenic mechanism underlying the
disease. In support of this hypothesis are the data demonstrating
an impaired Th1 cytokine production from IPEX T cells, with rel￾ative increase of Th2 cytokines (Chatila et al., 2000; Nieves et al.,
2004; Bacchetta et al., 2006). In addition, we observed an increased
proportion of IL-17 producing cells in the patients’ PBMC, which
could be derived in part from converted Treg, as mentioned above,
or in part from Teff cells.
Overall, our current view of the pathogenesis of IPEX syndrome
is that, even if impairment of Treg function is the major step, other
factors such as inflammation and Th17 elevation can cooperate in
maintaining and perpetuating the immune-dysfunction.
THERAPY
Due to the limited and sporadic number of cases reported in
literature, it has been difficult up to now to compare different
therapeutic strategies and relative outcomes. Therefore, the ther￾apeutic approaches for the treatment of IPEX patients are still
based on the experiences in single patients. Moreover, given the
unclear genotype-phenotype correlation, the clinical course of the
disease and the response to therapy can be variable and not always
satisfying. Therapy is therefore targeted to the clinical manifesta￾tions and severity of the individual patient. The current treatments
available for IPEX syndrome include replacement and supportive
therapy, IS therapy, and hematopoietic stem cell transplantation
(HSCT). Nutritional support and IS therapy should be promptly
started to counteract the initial acute manifestations. A wasting
syndrome can acutely affect the outcome of these patients, calling
for a collaborative multi-disciplinary effort among clinicians from
different specialties such as gastroenterology, infectious disease,
and immunohematology.
REPLACEMENT AND SUPPORT THERAPY
At onset, the patient should be hospitalized and receive a broad￾spectrum supportive care (fluids, TPN, albumin) with replace￾ment therapy for endocrine disorders (e.g., insulin and/or thyroid
hormones), autoimmune cytopenias (e.g., hemocomponents), or
hypogammaglobulinemia (e.g., intravenous immunoglobulins).
Prophylactic antibiotics should be used considering the multi￾ple potential sources of infection such as skin lesion, damaged
gastrointestinal lining, and central venous catheter. Infectious
episodes can drastically exacerbate or complicate the existing
clinical symptoms, endangering the patient’s life.
IMMUNOSUPPRESSIVE THERAPY
Monotherapy or combination immunosuppression reported so far
has shown to be only partially effective in controlling the autoim￾mune manifestations. Multiple IS therapies are often required to
control symptoms (Gambineri et al., 2008).
Glucocorticoids (prednisone and methylprednisolone) are
used as the first line therapy to limit progression of organ dam￾age (Gambineri et al., 2008). If the response to prednisone is
inadequate, betamethasone (the equivalent oral dose) could have
significantly better efficacy (Kobayashi et al., 2001; Taddio et al.,
2007). Then other IS drugs can be added onto the steroids regimen.
Cyclosporine and/or tacrolimus have been most commonly used
in conjunction with steroids (Baud et al., 2001; Wildin et al., 2002;
Mazzolari et al., 2005; Taddio et al., 2007; Gambineri et al., 2008).
Azathioprine also has been used with steroids and/or tacrolimus
with partial control of the disease (Bindl et al., 2005). The ideal
dose of medication should be determined to maximize clinical
benefit of the individual patient while minimizing side effects.
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 19

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Thanks to a better understand the disease pathogenesis, clini￾cians nowadays tend to choose more specific IS drugs, based on
the medication’s mechanism of action. Calcineurin inhibitors have
partial efficacy with high toxicity and simultaneously suppress Teff
cells, expression of FOXP3, and Treg cell function. On the contrary,
rapamycin selectively target Teff cells and do not interfere with the
function of Treg cells, which are insensitive to mTOR inhibitors
(Battaglia et al., 2006; Allan et al., 2008). Even if it is not clear if
FOXP3mut Treg cells respond to rapamycin in the same way as
FOXP3wt, the use of rapamycin (alone or in combination with
azathioprine or steroids) has given promising clinical results in
four IPEX cases (Bindl et al., 2005; Gambineri et al., 2008; Yong
et al., 2008). In these reports, rapamycin was used not as a first line
therapy, but as a second choice when calcineurin inhibitor failed.
The dosage used (approximately 0.15 mg/kg/day) was adjusted to
maintain serum levels between 8 and 12 ng/mL. In three patients
with IPEX syndrome, the combination of rapamycin, methotrex￾ate, and steroid (in one case) and rapamycin, steroid, and azathio￾prine (in the other two) allowed to obtain clinical remission in all
cases and maintain it over time (follow-up of 5 years, 6 months,
and 1.5 years, respectively; Bindl et al., 2005). The same positive
effect was achieved in one patient with rapamycin and steroid,
and with rapamycin monotherapy in another. Both showed clin￾ical remission with a follow-up of 21 and 15 months, respectively
(Yong et al., 2008). Based on these positive responses to rapamycin,
its use as the first line IS drug in conjunction with steroid might be
considered instead of calcineurin inhibitors. Of note, administra￾tion of rapamycin should be accompanied by frequent monitoring
of serum drug level with appropriate dose adjustment, since the
enteropathy may affect the drug intestinal absorption.
In IPEX patients who survived the first years of life, immuno￾suppression may stabilize the existing symptoms, but flares of
the disease may occur and new symptoms may arise despite the
therapy.
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Currently, the only cure for IPEX syndrome is allogeneic HSCT. A
summary of the published data regarding HSCT in IPEX patients
is provided in Table 5. Early HSCT leads to the best outcome, as the
organs are yet to be damaged from autoimmunity and the adverse
effects of therapy. For this reason it is fundamental to ensure an
early diagnosis. Twenty-eight cases reported received HSCT, 6 out
of these 28 patients died despite HSCT or during conditioning
(Table 1).
Among the 15 cases of transplanted IPEX patients reported
in detail (Table 5), half of them (8/15) received the transplant
before 1 year of age, one of whom died. Among the other half,
two patients who received the transplant at 9 and 13 years of age
died of infections shortly after. More recently a 16-year-old patient
underwent HSCT and a 1-year follow-up was reported. Despite the
unfortunate outcome in some patients, the HSCT should be always
recommended as the therapy of choice.
Both myeloablative and non-myeloablative conditioning regi￾mens were used in order to limit complications associated with
transplantation. The non-myeloablative regimens may enable
reduction of both the post-transplant infectious complications
and the toxicity of high dose chemotherapy. IPEX patients are
very susceptible to the side effects of chemotherapy because of
their poor clinical conditions. The use of a non-myeloablative
conditioning can more easily result in a partial chimerism.
Both related and unrelated matched donors were used success￾fully. Only one patient received HSC from cord blood (Lucas et al.,
2007) and three from mobilized peripheral blood (Zhan et al.,
2008; Seidel et al., 2009; Burroughs et al., 2010), otherwise bone
marrow was used as source of HSC (Baud et al., 2001;Wildin et al.,
2002; Mazzolari et al., 2005; Rao et al., 2007; Dorsey et al., 2009).
The longest follow-up reported is approximately 8 years post￾HSCT for three patients, including one patient transplanted at
our Institute (unpublished observations: E. Mazzolari; M. Sei￾del; R. Bacchetta). Only one of these patients reached full-donor
chimerism, however other cases with favorable outcome despite
partial chimerism have been described. Therefore, complete donor
engraftment in all hematopoietic lineages may not be necessary,
but the preferential engraftment of donor Treg cells does indicate
that at least the replacement of this cell subset is essential to cure
the disease (Seidel et al., 2009). In light of this observation, the
choice of drugs for GvHD prophylaxis should aim for the survival
of donor Treg cells.
Since wild type Treg cells seem to be sufficient to control the
disease,future cell/gene therapy approaches designed to selectively
restore the repertoire of Treg cells represent a promising oppor￾tunity. Constitutive lenti-viral mediated overexpression of FOXP3
into CD4+ T cells can convert Teff into Treg cells both in healthy
subject (Allan et al., 2008) and in IPEX patients with different
mutations (Passerini, in preparation). When a HLA compatible
donor is not available, treatment with engineered T cells could
be envisaged. Whether these cells would survive long enough to
provide a stable life-long immune regulation without generalized
immunosuppression remains to be clarified.
CONCLUSION
Immune dysregulation, polyendocrinopathy, enteropathy, X￾linked syndrome can be suspected on the basis of clinical and
laboratory features, and the timely recognition of the disease
leads to significant therapeutic benefits. A multicentre collab￾orative effort is desirable to implement studies in a wider
cohort of patients, in order to achieve a complete knowledge
of the disease, to better understand the factors that influence
the outcome, and to identify new therapeutic targets. Func￾tional impairment of Treg cells has been recognized as the pri￾mary defect at the basis of the immunodeficiency leading to
autoimmunity in IPEX syndrome. However, there is evidence
that FOXP3 mutations can contribute to a complex immune￾dysfunction, also involving Teff cells, and possibly other cell sub￾sets. Immunological studies on IPEX syndrome have been instru￾mental in other PID to identify Treg dysfunctions, independent
from FOXP3 mutations, as cause of autoimmunity and will
most likely advance the knowledge and the therapeutic perspec￾tives of other diseases with immune dysregulation of different
origin.
ACKNOWLEDGMENTS
The authors thank the members of the Italian Study Group of
IPEX (www.ipexconsortium.org). Our work is supported by the
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 20

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy Table 5 | Hematopoietic stem cell transplantation in IPEX patients. Baud et al. (2001) Wildin et al. (2002) Mazzolari et al. (2005) Lucas et al. (2007) Rao et al. (2007) Zhan et al. (2008) Seidel et al. (2009) Dorsey et al. (2009) Burroughs et al. (2010) Kasow et al. (2011) Age at onset 1 month 3 months 2 months 4 months <1 year na 2 months§ na na 4 months neonatal neonatal 2 months na 1.5 months Age at BMT 6 months 13 years 9 years 9 months 6 years 7 years 1 years 5 months 4 years 6 months 5 months 11 months 7 months 9 months 16 years 7 months Mutation c.1113 T>G c.1040G>A c.748_750 delAAG Promoter region Exon 10 Intron 9 c.303_304 delTT c.1271 G>A c.1226 A>G c.1139 C>T c.3G>A c.***878 A>G c.210 + 2 delT c.816 + 7 G>C c.1150 G>A Conditioning ATG, Bu, Cx Cx, TBI, ATG Flu, Bu, Cx, ATG Flu, Bu, ATG ALM, Flu, Melph ALM, Flu, Cx ALM, Flu, Melph ALM, Flu, Melph Flu, TBI ALM, Flu, Thio, Melph CD34+ source BM BM BM BM CB BM BM BM BM mPB mPB BM mPB BM BM Donor MRD MRD MUD MRD MUD, 5/6˚ MUD, 8/8˚ MUD, 7/8˚ MSD, 8/8˚ MUD, 8/8˚ MUD MUD, 10/10˚ MUD, 10/10˚ MUD MRD MUD***, 10/10˚ Chimerism (%) 100→30 100→50 100→70 70 (Treg 100) 98 na na na na 100 90 Treg, 10 WBC 100 100 100 100→30 Remission Yes* Yes Yes** Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes GvHD na No No No Gut 2˚ Gut 2˚ No No No Skin-gut, 2–3˚ Skin 2˚ Skin 2˚ Skin 2˚ Gut 2˚ No Outcome Exitus Exitus Exitus Alive Alive Alive Alive Alive Alive Alive Alive Alive Alive Alive Alive na, not available; ATG, anti-thymoglobulin; Bu, busulfan; Cx, cyclophosphamide;TBI, total body irradiation; Flu, fludarabine; ALM, alemtuzumab; Melph, melphalan;Thio, thiotepa; BM, bone marrow; CB, cord blood; mPB, mobilized peripheral blood; MRD, matched related donor; MUD, matched unrelated donor; GvHD, graft-versus-host disease. §The same case is reported also in Moudgil et al. (2007); ˚degree of HLA-match; *transient remission; **partial remission; ***T and B depleted.
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 21

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Telethon Foundation (Tele 10A4 to Rosa Bacchetta), the Italian
Ministry of Health (Grant RF-2009-1485896 to Rosa Bacchetta),
and the Seventh Framework project (FP7) of the European Com￾munity (Cell-PID to Rosa Bacchetta).The authors also thank
Minso Kim, a medical student at New York University, for help
in discussing and editing the present manuscript during her
international stay at HSR-TIGET; Massimiliano Cecconi, Human
Genetic Laboratory at Galliera Hospital, for helping in revision of
the reported mutations, and Dr. Graziano Barera for useful dis￾cussion on neonatal enteropathies. Lastly, we are grateful to the
patients and their families for their trust and participation in our
studies.
REFERENCES
Allan, S. E., Alstad, A. N., Merindol,
N., Crellin, N. K., Amendola, M.,
Bacchetta, R., Naldini, L., Roncarolo,
M. G., Soudeyns, H., and Levings,
M. K. (2008). Generation of potent
and stable human CD4+ T regula￾tory cells by activation-independent
expression of FOXP3. Mol. Ther. 16,
194–202.
Allan, S. E., Crome, S. Q., Crellin,
N. K., Passerini, L., Steiner, T.
S., Bacchetta, R., Roncarolo, M.
G., and Levings, M. K. (2007).
Activation-induced FOXP3 in
human T effector cells does not
suppress proliferation or cytokine
production. Int. Immunol. 19,
345–354.
Allan, S. E., Passerini, L., Bacchetta, R.,
Crellin, N., Dai, M., Orban, P. C.,
Ziegler, S. F., Roncarolo, M. G., and
Levings, M. K. (2005). The role of
2 FOXP3 isoforms in the generation
of human CD4+ Tregs.J. Clin. Invest.
115, 3276–3284.
An, Y. F., Xu, F., Wang, M., Zhang, Z.
Y., and Zhao, X. D. (2011). Clin￾ical and molecular characteristics
of immunodysregulation, polyen￾docrinopathy, enteropathy, X-linked
syndrome in China. Scand. J.
Immunol. 74, 304–309.
Bacchetta, R., Gambineri, E., and
Roncarolo, M. G. (2007). Role of
regulatory T cells and FOXP3 in
human diseases. J. Allergy Clin.
Immunol. 120, 227–235; quiz
236–227.
Bacchetta, R., Passerini, L., Gambineri,
E., Dai, M., Allan, S. E., Perroni,
L., Dagna-Bricarelli, F., Sartirana, C.,
Matthes-Martin, S., Lawitschka, A.,
Azzari, C., Ziegler, S. F., Levings, M.
K., and Roncarolo, M. G. (2006).
Defective regulatory and effector
T cell functions in patients with
FOXP3 mutations. J. Clin. Invest.
116, 1713–1722.
Bae, K. W., Kim, B. E., Choi, J. H.,
Lee, J. H., Park, Y. S., Kim, G. H.,
Yoo, H. W., and Seo, J. J. (2011). A
novel mutation and unusual clinical
features in a patient with immune
dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX)
syndrome. Eur. J. Pediatr. 170,
1611–1615.
Baron, U., Floess, S., Wieczorek, G.,
Baumann, K., Grutzkau, A., Dong,
J., Thiel, A., Boeld, T. J., Hoff￾mann, P., Edinger, M., Turbachova,
I., Hamann, A., Olek, S., and Huehn,
J. (2007). DNA demethylation in the
human FOXP3 locus discriminates
regulatory T cells from activated
FOXP3(+) conventional T cells. Eur.
J. Immunol. 37, 2378–2389.
Barzaghi, F., Passerini, L., Gambineri,
E., Ciullini Mannurita, S., Cornu,
T., Kang, E. S., Choe, Y. H., Can￾crini, C., Corrente, S., Ciccocioppo,
R., Cecconi, M., Zuin, G., Discepolo,
V., Sartirana, C., Schmidtko, J., Ikin￾ciogullari, A., Ambrosi, A., Roncar￾olo, M. G., Olek, S., and Bacchetta,
R. (2012). Demethylation analysis of
the FOXP3 locus shows quantita￾tive defects of regulatory T cells in
IPEX-like syndrome. J. Autoimmun.
38, 49–58.
Battaglia, M., Stabilini, A., Migliavacca,
B.,Horejs-Hoeck, J.,Kaupper,T., and
Roncarolo,M. G. (2006). Rapamycin
promotes expansion of functional
CD4+CD25+FOXP3+ regulatory T
cells of both healthy subjects and
type 1 diabetic patients. J. Immunol.
177, 8338–8347.
Baud, O., Goulet, O., Canioni, D.,
Le Deist, F., Radford, I., Rieu, D.,
Dupuis-Girod, S., Cerf-Bensussan,
N., Cavazzana-Calvo, M., Brousse,
N., Fischer, A., and Casanova, J. L.
(2001). Treatment of the immune
dysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome
(IPEX) by allogeneic bone marrow
transplantation. N. Engl. J. Med. 344,
1758–1762.
Bennett, C. L., Brunkow, M. E., Rams￾dell, F., O’Briant, K. C., Zhu, Q.,
Fuleihan, R. L., Shigeoka, A. O.,
Ochs, H. D., and Chance, P. F.
(2001a). A rare polyadenylation sig￾nal mutation of the FOXP3 gene
(AAUAAA→AAUGAA) leads to
the IPEX syndrome.Immunogenetics
53, 435–439.
Bennett, C. L., Christie, J., Ramsdell,
F., Brunkow, M. E., Ferguson, P. J.,
Whitesell, L., Kelly, T. E., Saulsbury,
F. T., Chance, P. F., and Ochs, H.
D. (2001b). The immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked syndrome (IPEX) is
caused by mutations of FOXP3. Nat.
Genet. 27, 20–21.
Bennett, C. L., Yoshioka, R., Kiyo￾sawa, H., Barker, D. F., Fain, P. R.,
Shigeoka, A. O., and Chance, P.
F. (2000). X-Linked syndrome of
polyendocrinopathy, immune dys￾function, and diarrhea maps to
Xp11.23-Xq13.3.Am. J. Hum. Genet.
66, 461–468.
Bindl, L., Torgerson, T., Perroni,
L., Youssef, N., Ochs, H. D.,
Goulet, O., and Ruemmele, F. M.
(2005). Successful use of the new
immune-suppressor sirolimus in
IPEX (immune dysregulation, poly￾endocrinopathy, enteropathy, X￾linked syndrome). J. Pediatr. 147,
256–259.
Burroughs, L. M., Storb, R., Leisenring,
W. M., Pulsipher, M. A., Loken,
M. R., Torgerson, T. R., Ochs, H.
D., and Woolfrey, A. E. (2007).
Intensive postgrafting immune
suppression combined with non￾myeloablative conditioning for
transplantation of HLA-identical
hematopoietic cell grafts: results
of a pilot study for treatment of
primary immunodeficiency disor￾ders. Bone Marrow Transplant. 40,
633–642.
Burroughs, L. M., Torgerson, T. R.,
Storb, R., Carpenter, P. A., Rawlings,
D. J., Sanders, J., Scharenberg, A. M.,
Skoda-Smith, S., Englund, J., Ochs,
H. D., and Woolfrey, A. E. (2010).
Stable hematopoietic cell engraft￾ment after low-intensity nonmye￾loablative conditioning in patients
with immune dysregulation, polyen￾docrinopathy, enteropathy, X-linked
syndrome. J. Allergy Clin. Immunol.
126, 1000–1005.
Chatila, T. A., Blaeser, F., Ho, N., Led￾erman, H. M., Voulgaropoulos, C.,
Helms, C., and Bowcock, A. M.
(2000). JM2, encoding a fork head￾related protein, is mutated in X￾linked autoimmunity-allergic dis￾regulation syndrome. J. Clin. Invest.
106, R75–R81.
Costa-Carvalho, B. T.,De Moraes-Pinto,
M. I., De Almeida, L. C., De Seixas
Alves, M. T., Maia, R. P., De Souza, R.
L.,Barreto,M., Lourenco, L.,Vicente,
A. M., Coutinho, A., and Carneiro￾Sampaio, M. (2008). A remark￾able depletion of both naive CD4+
and CD8+ with high proportion of
memory T cells in an IPEX infant
with a FOXP3 mutation in the fork￾head domain. Scand. J. Immunol. 68,
85–91.
De Benedetti, F., Insalaco, A., Dia￾manti, A., Cortis, E., Muratori, F.,
Lamioni, A., Carsetti, R., Cusano,
R., De Vito, R., Perroni, L., Gam￾barara, M., Castro, M., Bottazzo, G.
F., and Ugazio, A. G. (2006). Mech￾anistic associations of a mild phe￾notype of immunodysregulation,
polyendocrinopathy, enteropathy, x￾linked syndrome. Clin. Gastroen￾terol. Hepatol. 4, 653–659.
D’Hennezel, E., Ben-Shoshan,M., Ochs,
H. D., Torgerson, T. R., Russell, L.
J., Lejtenyi, C., Noya, F. J., Jabado,
N., Mazer, B., and Piccirillo, C. A.
(2009). FOXP3 forkhead domain
mutation and regulatory T cells in
the IPEX syndrome. N. Engl. J. Med.
361, 1710–1713.
Di Nunzio, S., Cecconi, M., Passerini,
L., Mcmurchy, A. N., Baron, U., Tur￾bachova, I., Vignola, S., Valencic, E.,
Tommasini, A., Junker, A., Cazzola,
G., Olek, S., Levings, M. K., Perroni,
L., Roncarolo, M. G., and Bacchetta,
R. (2009).Wild-type FOXP3 is selec￾tively active in CD4+CD25(hi) reg￾ulatory T cells of healthy female car￾riers of different FOXP3 mutations.
Blood 114, 4138–4141.
Dorsey, M. J., Petrovic, A., Morrow, M.
R., Dishaw, L. J., and Sleasman, J. W.
(2009). FOXP3 expression follow￾ing bone marrow transplantation
for IPEX syndrome after reduced￾intensity conditioning. Immunol.
Res. 44, 179–184.
Edghill, E. L., Flanagan, S. E., Patch, A.
M., Boustred, C., Parrish, A., Shields,
B., Shepherd, M. H., Hussain, K.,
Kapoor, R. R., Malecki, M., Mac￾donald, M. J., Stoy, J., Steiner, D.
F., Philipson, L. H., Bell, G. I., Hat￾tersley, A. T., and Ellard, S. (2008).
Insulin mutation screening in 1,044
patients with diabetes: mutations
in the INS gene are a common
cause of neonatal diabetes but a rare
cause of diabetes diagnosed in child￾hood or adulthood. Diabetes 57,
1034–1042.
Ferguson, P. J., Blanton, S. H., Saulsbury,
F. T., Mcduffie, M. J., Lemahieu,
V., Gastier, J. M., Francke, U.,
Borowitz, S. M., Sutphen, J. L., and
Kelly, T. E. (2000). Manifestations
and linkage analysis in X-linked
autoimmunity-immunodeficiency
syndrome. Am. J. Med. Genet. 90,
390–397.
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 22

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Fontenot, J. D., Gavin, M. A., and
Rudensky, A. Y. (2003). Foxp3 pro￾grams the development and func￾tion of CD4+CD25+ regulatory T
cells. Nat. Immunol. 4, 330–336.
Fraitag, S., and Bodemer, C. (2010).
Neonatal erythroderma. Curr. Opin.
Pediatr. 22, 438–444.
Fuchizawa, T., Adachi, Y., Ito, Y.,
Higashiyama, H., Kanegane, H.,
Futatani, T., Kobayashi, I., Kamachi,
Y., Sakamoto, T., Tsuge, I., Tanaka,
H., Banham, A. H., Ochs, H. D., and
Miyawaki, T. (2007). Developmen￾tal changes of FOXP3-expressing
CD4+CD25+ regulatory T cells
and their impairment in patients
with FOXP3 gene mutations. Clin.
Immunol. 125, 237–246.
Gambineri, E., Perroni, L., Passerini, L.,
Bianchi, L., Doglioni, C., Meschi, F.,
Bonfanti, R., Sznajer, Y., Tommasini,
A., Lawitschka, A., Junker, A., Dun￾stheimer, D., Heidemann, P. H., Caz￾zola, G., Cipolli, M., Friedrich, W.,
Janic, D., Azzi, N., Richmond, E.,
Vignola, S., Barabino, A., Chiumello,
G., Azzari, C., Roncarolo, M. G., and
Bacchetta, R. (2008). Clinical and
molecular profile of a new series
of patients with immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked syndrome: inconsis￾tent correlation between forkhead
box protein 3 expression and disease
severity. J. Allergy Clin. Immunol.
122, 1105–1112.e1101.
Gambineri, E., Torgerson, T. R., and
Ochs, H. D. (2003). Immune
dysregulation, polyendocrinopathy,
enteropathy, and X-linked inheri￾tance (IPEX), a syndrome of sys￾temic autoimmunity caused by
mutations of FOXP3, a criti￾cal regulator of T-cell homeosta￾sis. Curr. Opin. Rheumatol. 15,
430–435.
Gavin,M. A., Rasmussen, J. P., Fontenot,
J. D., Vasta, V., Manganiello, V.
C., Beavo, J. A., and Rudensky, A.
Y. (2007). Foxp3-dependent pro￾gramme of regulatory T-cell differ￾entiation. Nature 445, 771–775.
Gavin, M. A., Torgerson, T. R., Hous￾ton, E., Deroos, P., Ho, W. Y., Stray￾Pedersen,A., Ocheltree, E. L., Green￾berg, P. D., Ochs, H. D., and Ruden￾sky, A. Y. (2006). Single-cell analy￾sis of normal and FOXP3-mutant
human T cells: FOXP3 expression
without regulatory T cell develop￾ment. Proc. Natl. Acad. Sci. U.S.A.
103, 6659–6664.
Geha, R. S., Notarangelo, L. D.,
Casanova, J. L., Chapel, H., Conley,
M. E., Fischer, A., Hammarstrom,
L., Nonoyama, S., Ochs, H. D.,
Puck, J. M., Roifman, C., Seger,
R., and Wedgwood, J. (2007). Pri￾mary immunodeficiency diseases: an
updatefrom the International Union
of Immunological Societies Primary
Immunodeficiency Diseases Classi￾fication Committee. J. Allergy Clin.
Immunol. 120, 776–794.
Greeley, S. A., Tucker, S. E., Worrell,
H. I., Skowron, K. B., Bell, G. I.,
and Philipson, L. H. (2010). Update
in neonatal diabetes. Curr. Opin.
Endocrinol. Diabetes Obes. 17, 13–19.
Halabi-Tawil, M., Ruemmele, F. M.,
Fraitag, S., Rieux-Laucat, F., Neven,
B., Brousse, N., De Prost, Y., Fis￾cher, A., Goulet, O., and Bodemer,
C. (2009). Cutaneous manifestations
of immune dysregulation, polyen￾docrinopathy, enteropathy, X-linked
(IPEX) syndrome. Br. J. Dermatol.
160, 645–651.
Harbuz, R., Lespinasse, J., Boulet,
S., Francannet, C., Creveaux, I.,
Benkhelifa, M., Jouk, P. S., Lunardi,
J., and Ray, P. F. (2010). Identification
of new FOXP3 mutations and pre￾natal diagnosis of IPEX syndrome.
Prenat. Diagn. 30, 1072–1078.
Hashimura, Y., Nozu, K., Kanegane,
H., Miyawaki, T., Hayakawa, A.,
Yoshikawa, N., Nakanishi, K., Take￾moto, M., Iijima, K., and Matsuo, M.
(2009). Minimal change nephrotic
syndrome associated with immune
dysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome.
Pediatr. Nephrol. 24, 1181–1186.
Hattersley, A., Bruining, J., Shield, J.,
Njolstad, P., and Donaghue, K. C.
(2009). The diagnosis and manage￾ment of monogenic diabetes in chil￾dren and adolescents. Pediatr. Dia￾betes 10(Suppl. 12), 33–42.
Heltzer, M. L., Choi, J. K., Ochs, H.
D., Sullivan, K. E., Torgerson, T. R.,
and Ernst, L. M. (2007). A potential
screening tool for IPEX syndrome.
Pediatr. Dev. Pathol. 10, 98–105.
Hoeger, P. H., and Harper, J. I. (1998).
Neonatal erythroderma: differential
diagnosis and management of the
“red baby.” Arch. Dis. Child. 79,
186–191.
Huter, E. N., Natarajan, K., Torgerson,
T. R., Glass, D. D., and Shevach, E.
M. (2010). Autoantibodies in scurfy
mice and IPEX patients recognize
keratin 14. J. Invest. Dermatol. 130,
1391–1399.
Kasow, K. A., Morales-Tirado, V. M.,
Wichlan, D., Shurtleff, S. A., Abra￾ham, A., Persons, D. A., and Riberdy,
J. M. (2011). Therapeutic in vivo
selection of thymic-derived natural
T regulatory cells following non￾myeloablative hematopoietic stem
cell transplant for IPEX. Clin.
Immunol. 141, 169–176.
Kobayashi, I., Imamura, K., Kubota, M.,
Ishikawa, S., Yamada, M., Tonoki,
H., Okano, M., Storch, W. B.,
Moriuchi, T., Sakiyama, Y., and
Kobayashi, K. (1999). Identifica￾tion of an autoimmune enteropathy￾related 75-kilodalton antigen. Gas￾troenterology 117, 823–830.
Kobayashi, I., Imamura, K., Yamada,
M., Okano, M., Yara, A., Ikema,
S., and Ishikawa, N. (1998). A 75-
kD autoantigen recognized by sera
from patients with X-linked autoim￾mune enteropathy associated with
nephropathy. Clin. Exp. Immunol.
111, 527–531.
Kobayashi, I., Kubota, M., Yamada, M.,
Tanaka, H., Itoh, S., Sasahara, Y.,
Whitesell, L., and Ariga, T. (2011).
Autoantibodies to villin occur fre￾quently in IPEX, a severe immune
dysregulation, syndrome caused by
mutation of FOXP3. Clin. Immunol.
141, 83–89.
Kobayashi, I., Shiari, R., Yamada, M.,
Kawamura, N., Okano, M., Yara,
A., Iguchi, A., Ishikawa, N., Ariga,
T., Sakiyama, Y., Ochs, H. D., and
Kobayashi, K. (2001). Novel muta￾tions of FOXP3 in two Japanese
patients with immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X linked syndrome (IPEX). J.
Med. Genet. 38, 874–876.
Leclerc-Mercier, S., Bodemer, C.,
Bourdon-Lanoy, E., Larousserie,
F., Hovnanian, A., Brousse, N.,
and Fraitag, S. (2010). Early skin
biopsy is helpful for the diagnosis
and management of neonatal and
infantile erythrodermas. J. Cutan.
Pathol. 37, 249–255.
Lee,Y. K.,Mukasa, R., Hatton, R. D., and
Weaver, C. T. (2009). Developmen￾tal plasticity of Th17 and Treg cells.
Curr. Opin. Immunol. 21, 274–280.
Levy-Lahad, E., and Wildin, R. S.
(2001). Neonatal diabetes mellitus,
enteropathy, thrombocytopenia, and
endocrinopathy: further evidence
for an X-linked lethal syndrome. J.
Pediatr. 138, 577–580.
Lopez, S. I., Ciocca, M., Oleastro, M.,
Cuarterolo, M. L., Rocca, A., De
Davila, M. T., Roy, A., Fernandez, M.
C., Nievas, E., Bosaleh, A., Torger￾son, T. R., and Ruiz, J. A. (2011).
Autoimmune hepatitis type 2 in a
child with IPEX syndrome.J. Pediatr.
Gastroenterol. Nutr. 53, 690–693.
Lucas, K. G., Ungar, D., Comito, M.,
Bayerl,M., and Groh, B. (2007). Sub￾myeloablative cord blood transplan￾tation corrects clinical defects seen
in IPEX syndrome. Bone Marrow
Transplant. 39, 55–56.
Lucas, K. G., Ungar, D., Comito, M.,
and Groh, B. (2008). Epstein Barr
virus induced lymphoma in a child
with IPEX syndrome. Pediatr Blood
Cancer 50, 1056–1057.
Marangoni, F., Trifari, S., Scara￾muzza, S., Panaroni, C., Martino, S.,
Notarangelo, L. D., Baz, Z., Metin,
A., Cattaneo, F., Villa, A., Aiuti, A.,
Battaglia, M., Roncarolo, M. G., and
Dupre, L. (2007). WASP regulates
suppressor activity of human and
murine CD4(+)CD25(+)FOXP3(+)
natural regulatory T cells. J. Exp.
Med. 204, 369–380.
Mazzolari, E., Forino, C., Fontana, M.,
D’Ippolito, C., Lanfranchi, A., Gam￾bineri, E., Ochs, H., Badolato, R., and
Notarangelo, L. D. (2005). A new
case of IPEX receiving bone mar￾row transplantation. Bone Marrow
Transplant. 35, 1033–1034.
McGinness, J. L., Bivens, M. M., Greer,
K. E., Patterson, J. W., and Saulsbury,
F. T. (2006). Immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked syndrome (IPEX) asso￾ciated with pemphigoid nodularis:
a case report and review of the lit￾erature. J. Am. Acad. Dermatol. 55,
143–148.
McLucas, P., Fulchiero, G. J. Jr., Fernan￾dez, E., Miller, J. J., and Zaenglein, A.
L. (2007). Norwegian scabies mim￾icking onychomycosis and scalp der￾matitis in a child with IPEX syn￾drome. J. Am. Acad. Dermatol. 56,
S48–S49.
McMurchy, A. N., Gillies, J., Allan,
S. E., Passerini, L., Gambineri,
E., Roncarolo, M. G., Bacchetta,
R., and Levings, M. K. (2010).
Point mutants of forkhead box
P3 that cause immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked have diverse abilities to
reprogram T cells into regulatory T
cells. J. Allergy Clin. Immunol. 126,
1242–1251.
Moes, N., Rieux-Laucat, F., Begue, B.,
Verdier, J., Neven, B., Patey, N., Torg￾erson, T. T., Picard, C., Stolzenberg,
M. C., Ruemmele, C., Rings, E. H.,
Casanova, J. L., Piloquet, H., Biver,
A., Breton, A., Ochs, H. D., Her￾mine, O., Fischer, A., Goulet, O.,
Cerf-Bensussan, N., and Ruemmele,
F. M. (2010). Reduced expression of
FOXP3 and regulatory T-cell func￾tion in severe forms of early-onset
autoimmune enteropathy. Gastroen￾terology 139, 770–778.
Moudgil, A., Perriello, P., Loechelt, B.,
Przygodzki, R., Fitzerald, W., and
Kamani, N. (2007). Immunodys￾regulation, polyendocrinopathy,
enteropathy, X-linked (IPEX)
syndrome: an unusual cause of
proteinuria in infancy. Pediatr.
Nephrol. 22, 1799–1802.
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 23

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
Murch, S. H. (1997). The molecu￾lar basis of intractable diarrhoea
of infancy. Baillieres Clin. Gastroen￾terol. 11, 413–440.
Murch, S. H. (2001). Unusual
enteropathies. Gastrointest. Endosc.
Clin. N. Am. 11, 741–766, vii.
Murch, S. H. (2006). “Protracted diar￾rhea,” in Pediatric Gastrointestinal
and Liver Disease, 3rd Edn, eds J. S.
Hyams and R. Wylley (Amsterdam:
Elsevier), 279–287.
Myers, A. K., Perroni, L., Costigan, C.,
and Reardon, W. (2006). Clinical
and molecular findings in IPEX syn￾drome. Arch. Dis. Child. 91, 63–64.
Nieves, D. S., Phipps, R. P., Pollock, S.
J., Ochs, H. D., Zhu, Q., Scott, G.
A., Ryan, C. K., Kobayashi, I., Rossi,
T. M., and Goldsmith, L. A. (2004).
Dermatologic and immunologic
findings in the immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked syndrome. Arch Der￾matol 140, 466–472.
Ochs, H. D., and Torgerson, T.
R. (2007). Immune dysregula￾tion, polyendocrinopathy, enteropa￾thy, X-linked inheritance: model for
autoaggression. Adv. Exp. Med. Biol.
601, 27–36.
Otsubo, K., Kanegane, H., Kamachi, Y.,
Kobayashi, I., Tsuge, I., Imaizumi,
M., Sasahara, Y., Hayakawa, A.,
Nozu, K., Iijima, K., Ito, S.,
Horikawa, R., Nagai, Y., Takatsu,
K., Mori, H., Ochs, H. D., and
Miyawaki, T. (2011). Identification
of FOXP3-negative regulatory T-like
(CD4(+)CD25(+)CD127(low))
cells in patients with immune
dysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome.
Clin. Immunol. 141, 111–120.
Owen, C. J., Jennings, C. E., Imrie,
H., Lachaux, A., Bridges, N. A.,
Cheetham, T. D., and Pearce,
S. H. (2003). Mutational analy￾sis of the FOXP3 gene and evi￾dence for genetic heterogeneity
in the immunodysregulation, poly￾endocrinopathy, enteropathy syn￾drome. J. Clin. Endocrinol. Metab.
88, 6034–6039.
Passerini, L., Allan, S. E., Battaglia, M.,
Di Nunzio, S., Alstad, A. N., Levings,
M. K., Roncarolo, M. G., and Bac￾chetta, R. (2008). STAT5-signaling
cytokines regulate the expression of
FOXP3 in CD4+CD25+ regulatory
T cells and CD4+CD25- effector T
cells. Int. Immunol. 20, 421–431.
Passerini, L., Di Nunzio, S., Gregori,
S., Gambineri, E., Cecconi, M., Sei￾del, M. G., Cazzola, G., Perroni, L.,
Tommasini, A., Vignola, S., Guidi,
L., Roncarolo, M. G., and Bac￾chetta, R. (2011a). Functional type 1
regulatory T cells develop regardless
of FOXP3 mutations in patients with
IPEX syndrome. Eur. J. Immunol. 41,
1120–1131.
Passerini, L., Olek, S., Di Nunzio, S.,
Barzaghi, F., Hambleton, S., Abi￾nun, M., Tommasini, A., Vignola, S.,
Cipolli, M., Amendola, M., Naldini,
L., Guidi, L., Cecconi,M., Roncarolo,
M. G., and Bacchetta, R. (2011b).
Forkhead box protein 3 (FOXP3)
mutations lead to increased TH17
cell numbers and regulatory T-cell
instability. J. Allergy Clin. Immunol.
128, 1376–1379.e1371.
Patey-Mariaud de Serre, N., Can￾ioni, D., Ganousse, S., Rieux￾Laucat, F., Goulet, O., Ruemmele,
F., and Brousse, N. (2009). Diges￾tive histopathological presentation
of IPEX syndrome. Mod. Pathol. 22,
95–102.
Peake, J. E., Mccrossin, R. B., Byrne, G.,
and Shepherd, R. (1996). X-linked
immune dysregulation, neonatal
insulin dependent diabetes, and
intractable diarrhoea. Arch. Dis.
Child. Fetal Neonatal Ed. 74, F195–
F199.
Porter, J. R., and Barrett, T. G. (2004).
Acquired non-type 1 diabetes in
childhood: subtypes, diagnosis, and
management. Arch. Dis. Child. 89,
1138–1144.
Powell, B. R., Buist, N. R., and Stenzel,
P. (1982). An X-linked syndrome of
diarrhea, polyendocrinopathy, and
fatal infection in infancy. J. Pediatr.
100, 731–737.
Rao, A., Kamani, N., Filipovich, A.,
Lee, S. M., Davies, S. M., Dalal,
J., and Shenoy, S. (2007). Success￾ful bone marrow transplantation
for IPEX syndrome after reduced￾intensity conditioning. Blood 109,
383–385.
Redding, A. R., Lew, D. B., Conley, M.
E., and Pivnick, E. K. (2009). An
infant with erythroderma, skin scal￾ing, chronic emesis, and intractable
diarrhea. Clin. Pediatr. (Phila.) 48,
978–980.
Roncarolo, M. G., Gregori, S., Battaglia,
M., Bacchetta, R., Fleischhauer,
K., and Levings, M. K. (2006).
Interleukin-10-secreting type 1 reg￾ulatory T cells in rodents and
humans. Immunol. Rev. 212, 28–50.
Rubio-Cabezas, O., Klupa, T., and
Malecki, M. T. (2010). Permanent
neonatal diabetes mellitus – the
importance of diabetes differential
diagnosis in neonates and infants.
Eur. J. Clin. Invest. 41, 323–333.
Rubio-Cabezas, O., Minton, J. A.,
Caswell, R., Shield, J. P., Deiss,
D., Sumnik, Z., Cayssials, A., Herr,
M., Loew, A., Lewis, V., Ellard, S.,
and Hattersley, A. T. (2009). Clin￾ical heterogeneity in patients with
FOXP3 mutations presenting with
permanent neonatal diabetes. Dia￾betes Care 32, 111–116.
Rubtsov, Y. P., Niec, R. E., Josefowicz, S.,
Li, L., Darce, J., Mathis, D., Benoist,
C., and Rudensky, A. Y. (2010). Sta￾bility of the regulatory T cell lineage
in vivo. Science 329, 1667–1671.
Ruemmele, F. M., Moes, N., De
Serre, N. P., Rieux-Laucat, F., and
Goulet, O. (2008). Clinical and
molecular aspects of autoimmune
enteropathy and immune dysregu￾lation, polyendocrinopathy autoim￾mune enteropathy X-linked syn￾drome.Curr. Opin. Gastroenterol. 24,
742–748.
Sakaguchi, S. (2006). Regulatory T cells.
Springer Semin. Immunopathol. 28,
1–2.
Sauer, A. V., Brigida, I., Carriglio, N.,
Hernandez, R. J., Scaramuzza, S.,
Clavenna, D., Sanvito, F., Poliani, P.
L., Gagliani, N., Carlucci, F., Tabuc￾chi, A., Roncarolo, M. G., Trag￾giai, E., Villa, A., and Aiuti, A.
(2012). Alterations in the adeno￾sine metabolism and CD39/CD73
adenosinergic machinery cause loss
of Treg cell function and autoimmu￾nity in ADA-deficient SCID. Blood
119, 1428–1439.
Scaillon, M., Van Biervliet, S., Bon￾tems, P., Dorchy, H., Hanssens, L.,
Ferster, A., Segers, V., and Cad￾ranel, S. (2009). Severe gastritis in
an insulin-dependent child with an
IPEX syndrome.J. Pediatr. Gastroen￾terol. Nutr. 49, 368–370.
Seidel, M. G., Fritsch, G., Lion, T.,
Jurgens, B., Heitger, A., Bacchetta,
R., Lawitschka, A., Peters, C., Gad￾ner, H., and Matthes-Martin, S.
(2009). Selective engraftment of
donor CD4+25high FOXP3-positive
T cells in IPEX syndrome after non￾myeloablative hematopoietic stem
cell transplantation. Blood 113,
5689–5691.
Sherman, P. M.,Mitchell, D. J., and Cutz,
E. (2004). Neonatal enteropathies:
defining the causes of protracted
diarrhea of infancy. J. Pediatr. Gas￾troenterol. Nutr. 38, 16–26.
Suzuki, S., Makita, Y., Mukai, T., Mat￾suo, K., Ueda, O., and Fujieda, K.
(2007). Molecular basis of neonatal
diabetes in Japanese patients. J. Clin.
Endocrinol. Metab. 92, 3979–3985.
Taddio, A., Faleschini, E., Valencic, E.,
Granzotto, M., Tommasini, A., Lep￾ore, L., Andolina, M., Barbi, E.,
and Ventura, A. (2007). Medium￾term survival without haematopoi￾etic stem cell transplantation in
a case of IPEX: insights into
nutritional and immunosuppres￾sive therapy. Eur. J. Pediatr. 166,
1195–1197.
Tanaka, H., Tsugawa, K., Kudo, M., Sug￾imoto, K., Kobayashi, I., and Ito, E.
(2005). Low-dose cyclosporine A in
a patient with X-linked immune dys￾regulation, polyendocrinopathy and
enteropathy. Eur. J. Pediatr. 164,
779–780.
Torgerson, T. R., Linane, A., Moes,
N., Anover, S., Mateo, V., Rieux￾Laucat, F., Hermine, O., Vijay, S.,
Gambineri, E., Cerf-Bensussan, N.,
Fischer, A., Ochs, H. D., Goulet,
O., and Ruemmele, F. M. (2007).
Severe food allergy as a variant of
IPEX syndrome caused by a dele￾tion in a noncoding region of the
FOXP3 gene. Gastroenterology 132,
1705–1717.
Tran, D. Q., Ramsey, H., and She￾vach, E. M. (2007). Induction of
FOXP3 expression in naive human
CD4+FOXP3 T cells by T-cell
receptor stimulation is transform￾ing growth factor-beta dependent
but does not confer a regulatory
phenotype. Blood 110, 2983–2990.
Tsuda, M., Torgerson, T. R., Selmi, C.,
Gambineri, E., Carneiro-Sampaio,
M., Mannurita, S. C., Leung, P.
S., Norman, G. L., and Gersh￾win, M. E. (2010). The spec￾trum of autoantibodies in IPEX
syndrome is broad and includes
anti-mitochondrial autoantibodies.
J. Autoimmun. 35, 265–268.
Unsworth, D. J., and Walker-Smith, J. A.
(1985). Autoimmunity in diarrhoeal
disease. J. Pediatr. Gastroenterol.
Nutr. 4, 375–380.
Valamparampil, J. J., Chirakkarot, S.,
Savida, P., and Omana, S. (2009).
Clinical profile and etiology of dia￾betes mellitus with onset at less than
6 months of age. Kaohsiung J. Med.
Sci. 25, 656–662.
Wan, Y. Y., and Flavell, R. A. (2007).
Regulatory T-cell functions are sub￾verted and converted owing to atten￾uated Foxp3 expression. Nature 445,
766–770.
Wang, J., Li,X., Jia,Z.,Tian,Y.,Yu, J.,Bao,
L.,Wu,Y., and Ni, B. (2010). Reduced
FOXP3 expression causes IPEX syn￾drome onset: an implication from
an IPEX patient and his disease-free
twin brother. Clin. Immunol. 137,
178–180.
Wieczorek, G., Asemissen, A., Model,
F., Turbachova, I., Floess, S., Lieben￾berg, V., Baron, U., Stauch, D.,
Kotsch, K., Pratschke, J., Hamann,
A., Loddenkemper, C., Stein,
H., Volk, H. D., Hoffmuller, U.,
Grutzkau, A., Mustea, A., Huehn,
J., Scheibenbogen, C., and Olek, S.
Frontiers in Immunology | Primary Immunodeficiencies July 2012 | Volume 3 | Article 211 | 24

Barzaghi et al. IPEX: diagnosis, pathogenesis, and therapy
(2009). Quantitative DNA methy￾lation analysis of FOXP3 as a new
method for counting regulatory T
cells in peripheral blood and solid
tissue. Cancer Res. 69, 599–608.
Wildin, R. S., Ramsdell, F., Peake, J.,
Faravelli, F., Casanova, J. L., Buist,
N., Levy-Lahad, E., Mazzella, M.,
Goulet, O., Perroni, L., Bricarelli,
F. D., Byrne, G., Mceuen, M.,
Proll, S., Appleby, M., and Brunkow,
M. E. (2001). X-linked neonatal
diabetes mellitus, enteropathy and
endocrinopathy syndrome is the
human equivalent of mouse scurfy.
Nat. Genet. 27, 18–20.
Wildin, R. S., Smyk-Pearson, S.,
and Filipovich, A. H. (2002).
Clinical and molecular features
of the immunodysregulation,
polyendocrinopathy, enteropathy,
X linked (IPEX) syndrome. J. Med.
Genet. 39, 537–545.
Williams, L. M., and Rudensky, A. Y.
(2007). Maintenance of the Foxp3-
dependent developmental program
in mature regulatory T cells requires
continued expression of Foxp3. Nat.
Immunol. 8, 277–284.
Yong, P. L., Russo, P., and Sullivan, K. E.
(2008). Use of sirolimus in IPEX and
IPEX-like children. J. Clin. Immunol.
28, 581–587.
Zhan, H., Sinclair, J., Adams, S., Cale,
C. M., Murch, S., Perroni, L.,
Davies, G., Amrolia, P., and Qasim,
W. (2008). Immune reconstitution
and recovery of FOXP3 (forkhead
box P3)-expressing T cells after
transplantation for IPEX (immune
dysregulation, polyendocrinopathy,
enteropathy, X-linked) syndrome.
Pediatrics 121, e998–e1002.
Zhou, L., Chong, M. M., and Littman,
D. R. (2009). Plasticity of CD4+ T
cell lineage differentiation. Immu￾nity 30, 646–655.
Ziegler, S. F. (2006). FOXP3: of mice
and men. Annu. Rev. Immunol. 24,
209–226.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com￾mercial or financial relationships that
could be construed as a potential con￾flict of interest.
Received: 03 May 2012; accepted: 01 July
2012; published online: 31 July 2012.
Citation: Barzaghi F, Passerini L and
Bacchetta R (2012) Immune dysreg￾ulation, polyendocrinopathy, enteropa￾thy, X-linked syndrome: a paradigm
of immunodeficiency with autoim￾munity. Front. Immun. 3:211. doi:
10.3389/fimmu.2012.00211
This article was submitted to Frontiers in
Primary Immunodeficiencies, a specialty
of Frontiers in Immunology.
Copyright © 2012 Barzaghi, Passerini
and Bacchetta. This is an open-access
article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro￾vided the original authors and source
are credited and subject to any copy￾right notices concerning any third-party
graphics etc.
www.frontiersin.org July 2012 | Volume 3 | Article 211 | 25

